var title_f27_31_28144="Shoulder strength exercises";
var content_f27_31_28144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strengthening exercises for the rotator cuff tendons",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Part A: The inward rotation isometric exercise is performed by holding the elbow at 90&deg;, close to the side. The rubber band is hooked onto a door handle and grasped with the hand. The forearm is slowly moved towards the body two to three inches, and held for five seconds. The hand should not rotate as the forearm moves.",
"    <br>",
"     Part B: The outward rotation isometric exercise is performed with the elbows at 90&deg;, close to the sides. The rubber band is grasped with the hands. The formearms are moved outward two to three inches and held for five seconds. Sets of 15 to 20 exercises, each held for five seconds, should be performed daily.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Bruce C Anderson, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28144=[""].join("\n");
var outline_f27_31_28144=null;
var title_f27_31_28145="Surgical repair TOF";
var content_f27_31_28145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of tetralogy of Fallot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 411px; height: 307px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These figures depict two options for the surgical correction of right ventricular outflow tract (RVOT) obstruction in patients with tetralogy of Fallot. In figure A, the RVOT is enlarged by opening the RVOT and pulmonary valve, resecting the subinfundibular muscle bundles, and patching the area open. In figure B, a conduit containing a prosthetic valve is inserted to connect the right ventricle and the main pulmonary artery, bypassing the RVOT.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28145=[""].join("\n");
var outline_f27_31_28145=null;
var title_f27_31_28146="Posterior junction line CT";
var content_f27_31_28146=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior pleural junction line on chest CT scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows the posterior junction line formed by four layers of pleura that join posterior to the esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28146=[""].join("\n");
var outline_f27_31_28146=null;
var title_f27_31_28147="Flow cytometry basics";
var content_f27_31_28147=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Fundamentals of flow cytometry",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluorochrome (eg, fluorescein) conjugated directly to an antibody binds to a cell. Cells stained with fluorescein are stimulated by a laser emitting light of a wavelength significant to stimulate the fluorescein molecule. Fluorescence occurs when the molecule excited by light of a particular wavelength loses its energy by emitting light of a longer wavelength. The fluorescence spectra shown above demonstrates the excitation spectra of a fluorochrome (left), the wavelength of a typical laser source, the emission spectra of a fluorochrome (right), and the wavelength range detected by a typical band pass filter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28147=[""].join("\n");
var outline_f27_31_28147=null;
var title_f27_31_28148="Joint aspiration: The dry tap";
var content_f27_31_28148=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Joint aspiration: The dry tap",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28148/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28148/contributors\">",
"     W Neal Roberts, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28148/contributors\">",
"     Curtis W Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28148/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28148/contributors\">",
"     Daniel E Furst, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28148/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28148/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/31/28148/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In occasional patients, a joint that has obvious fluid on physical examination yields a &ldquo;dry tap&rdquo; during diagnostic arthrocentesis, even after the needle has been redirected and is clearly in the joint space. This problem comes up with surprising frequency with respect to the knee and also occurs with joints that are more difficult to tap, such as ankle and shoulder. The proper approach to a dry tap in an individual patient has to take into account, above all, the degree of suspicion of a",
"    <strong>",
"     septic joint",
"    </strong>",
"    . When joint fluid is necessary for diagnosis, consideration should be given both to the differential diagnosis of the causes of a dry tap and to a change in technique which this differential implies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES OF A DRY TAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three major explanations for a dry tap after extraarticular placement of the needle tip is excluded (",
"    <a class=\"graphic graphic_table graphicRef72363 \" href=\"UTD.htm?5/18/5419\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mistaken physical diagnosis",
"     </li>",
"     <li>",
"      Blockage of the bevel of the needle by plica, fat, or debris",
"     </li>",
"     <li>",
"      Very high viscosity fluid or true lipoma arborescens",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dry tap in the knee",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative frequency of the different possible explanations of failed arthrocentesis remains conjectural. Ultrasonography can often solve the practical problem of a dry tap if multiple unguided attempts fail. In addition, the advent of more sensitive imaging techniques, especially magnetic resonance imaging (MRI) of the knee, has permitted many of the explanations for failed arthrocentesis to be vividly illustrated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Probably the most common cause of failed arthrocentesis occurs when the examiner is mistaken and no joint effusion is present (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68585 \" href=\"UTD.htm?0/21/336\">",
"       image 1",
"      </a>",
"      ). Even the experienced clinician can make this mistake, particularly in the obese patient. However, a similar problem can occur in patients of average weight.",
"     </li>",
"     <li>",
"      Many subjects have a triangular fat pad at the medial aspect of the patellofemoral compartment, which is the most common site to attempt arthrocentesis of the knee. Placing the needle in this location may yield no fluid if the fat pad is thick (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72085 \" href=\"UTD.htm?34/0/34831\">",
"       image 2",
"      </a>",
"      ). The medial fat pad is the strongest individual reason for a switch from the medial to the lateral approach for a knee tap.",
"     </li>",
"     <li>",
"      Chronically inflamed synovium may undergo fat replacement over a period of time and may become markedly thickened, much more so than is indicated by examination of the surface anatomy (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef57209 \" href=\"UTD.htm?2/55/2933\">",
"       image 3",
"      </a>",
"      ). This condition, when severe, may be referred to as the pathologic entity of lipoma arborescens [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28148/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A commonly invoked, but rarely present, explanation for failed arthrocentesis in the knee is a medial plica (",
"      <a class=\"graphic graphic_picture graphicRef68856 \" href=\"UTD.htm?16/12/16576\">",
"       picture 1",
"      </a>",
"      ) which behaves as a dam or valve, obstructing the lumen of the needle (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79326 \" href=\"UTD.htm?20/0/20480\">",
"       image 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28148/abstract/3\">",
"       3",
"      </a>",
"      ]. Anatomically, a medial patella plica is very common. Symptomatic inflammation of the plica is rare. &ldquo;Dry tap&rdquo; due to a medial plica is rare. Lateral plicae are very rare.",
"     </li>",
"     <li>",
"      Fluid can also become inaccessible by one or more routes when joints have only a low volume of fluid or when the bevel becomes blocked by debris such as rice bodies or thick fibrin [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28148/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Highly viscous synovial fluid can be difficult or impossible to remove by smaller gauge needles, and increasing to a 20 or 18 gauge needle may be required. In some cases, the joint effusion consists of areas of free fluid along with other areas occupied by semisolid gelatinous material too viscous to be withdrawn (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65066 \" href=\"UTD.htm?0/39/628\">",
"       image 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28148/abstract/1\">",
"       1",
"      </a>",
"      ]. Failure to aspirate fluid from a popliteal (Baker's) cyst, for example, has sometimes been attributed to inspissation of joint fluid into a gelatinous mass which has fluid-like characteristics on physical examination but which is too viscous to be withdrawn even through a large gauge needle. Such inspissated &ldquo;pseudo-effusions&rdquo; are sometimes confirmed at surgery [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28148/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients have more than one cause for a dry tap, as with lipoma arborescens and a gelatinous effusion (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef51123 \" href=\"UTD.htm?2/24/2433\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dry tap in other joints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other joints not as well-studied by MRI retain their complexity in the &ldquo;dry tap&rdquo; situation. In particular, the several normal anatomic compartments of the shoulder often require more than one attempt by different routes, ultrasonography, or even arthroscopy.",
"   </p>",
"   <p>",
"    A dry tap in a patient with apparent bilateral ankle effusions may be due to a",
"    <strong>",
"     periarthritis",
"    </strong>",
"    without true effusion. This can occur in sarcoidosis and gout. In the latter disorder, a single drop of interstitial fluid expressed from needle puncture wound of an unsuccessful arthrocentesis can be applied to a slide for examination under polarized light.",
"   </p>",
"   <p>",
"    Unilateral ankle effusions can be crystal-induced &ldquo;cluster attacks&rdquo; in which several anatomically adjacent joints are involved. These latter attacks can sometimes be made to yield fluid by switching from the true ankle to the subtalar joint, one finger's breadth below the prominence of the lateral malleolus (",
"    <a class=\"graphic graphic_figure graphicRef66205 \" href=\"UTD.htm?22/1/22559\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT WITH A DRY TAP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8656257\">",
"    <span class=\"h2\">",
"     Ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography may be an effective tool for facilitating needle placement and arthrocentesis. However, the availability of this technique for use in the clinical setting varies widely due to potential costs of equipment, regulatory and reimbursement policies, and differences in experience and training between musculoskeletal clinicians. Ultrasonography can be used for direct guidance of needle insertion, with concurrent ultrasound visualization of the area for injection, or for indirect guidance, in which the target region is visualized for the purpose of marking the needle insertion site and of estimating the depth and direction of needle placement. The use of ultrasound guidance in rheumatology practice continues to evolve and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1991?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Clinical applications\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44536?source=see_link\">",
"     \"Musculoskeletal ultrasonography: Guided injection and aspiration of joints and related structures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Knee effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four important teaching points for the approach to dry taps of knee effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28148/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unsuccessful aspiration from the medial side should be followed by a lateral approach. Many prefer to attempt aspiration from the medial side first because the surface landmarks and shape of the patella are more obvious medially.",
"     </li>",
"     <li>",
"      A helpful maneuver in second attempts is to have a second operator compress the fluid from three sides of the knee. Ultrasonography should be performed if these two modalities are ineffective and if a septic joint is suspected.",
"     </li>",
"     <li>",
"      The physical examination can occasionally be falsely positive, even when performed by experienced examiners; MRI is the gold standard when this is suspected.",
"     </li>",
"     <li>",
"      With chronic effusions, it may be impossible to obtain fluid from either the medial or the lateral approach due to a gelatinous mass obstructing the needle (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef65066 \" href=\"UTD.htm?0/39/628\">",
"       image 5",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hip effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hip effusions are seen well on ultrasound in adults, as demonstrated in a study promoting the bedside use of joint ultrasonography in the rheumatologic setting [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28148/abstract/6\">",
"     6",
"    </a>",
"    ]. In children, however, more mobile femoral heads are sometimes pushed anteriorly, obscuring the existence of hip effusion from the vantage point of the anteriorly placed ultrasound window. US is useful for average to thin adults and is considered by pediatric radiologists to be the imaging modality of choice (over fluoroscopy) for children suspected of hip joint effusion. The standard imaging study for the hip requiring arthrocentesis remains arthrocentesis under fluoroscopy for heavier patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Shoulder effusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is less useful for the shoulder, since the acromion narrows the ultrasound window. In this setting, the special role of palpable shoulder effusion in suggesting a septic joint should be kept in mind. Weightbearing, lower-extremity joints develop effusions easily with relatively modest amounts of inflammation. In contrast, the shoulder is not weightbearing. It can be splinted involuntarily and can be rested by the patient without much conscious effort, with the elbow, wrist, and opposite arm taking up much of its role in the activities of daily living. This is why &ldquo;frozen&rdquo; shoulders are common and frozen knees are not.",
"   </p>",
"   <p>",
"    Thus, an acute or subacute shoulder effusion palpable on physical examination means severe inflammation that is unresponsive to rest and to splinting. A septic joint becomes that much more likely, particularly in a patient whose capacity to generate inflammation is already somewhat suppressed by NSAIDs, low-dose corticosteroids, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Palpable shoulder effusions, especially those that are unilateral and painful for an otherwise well-treated patient with RA, must be aspirated for cell count, culture, and crystal examination regardless of the technical difficulties.",
"   </p>",
"   <p>",
"    Both the traditional anterior approach and the posterior approach should be attempted. The anterior approach (one finger's breadth below and medial to the coracoid process) is more difficult in an obese patient than the adaptation of the posterior approach to the subdeltoid space. The site of the latter approach is one finger's breadth inferior and medial to the tip of the scapular spine, felt as a near 90&ordm; angle of bone behind the shoulder, angled 15&ordm; downward to penetrate the true glenohumeral joint instead of slightly superior, toward the thyroid to penetrate the subdeltoid space.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11369318\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A joint that appears to have an effusion on physical examination may occasionally yield a &ldquo;dry tap&rdquo; during diagnostic arthrocentesis, even after the needle has been redirected and is clearly in the joint space. Explanations for a dry tap that should be considered, after extraarticular placement of the needle tip is excluded, include mistaken physical diagnosis; blockage of the bevel of the needle by plica, fat, or debris; and very high viscosity fluid or true lipoma arborescens (",
"      <a class=\"graphic graphic_table graphicRef72363 \" href=\"UTD.htm?5/18/5419\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes of a dry tap'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of failed arthrocentesis of the knee may be the absence of a joint effusion, despite an apparent effusion on examination; this may occur more frequently in obese patients. Other causes include insertion of the needle into the fat pad sometimes present at the medial aspect of the patellofemoral compartment, fatty replacement of chronically inflamed synovium (lipoma arborescens), a low volume of fluid, blockage by debris, and use of a needle of insufficient gauge for a gelatinous effusion. The presence of multiple anatomic compartments in a joint, such as the shoulder, or periarthritis and swelling without true arthritis, as sometimes occurs in the ankle, are also potential causes. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dry tap in the knee'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Dry tap in other joints'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ultrasonography is often helpful in patients with a dry tap. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Approach to the patient with a dry tap'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=see_link\">",
"       \"Musculoskeletal ultrasonography: Clinical applications\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44536?source=see_link\">",
"       \"Musculoskeletal ultrasonography: Guided injection and aspiration of joints and related structures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Unsuccessful aspiration from the medial side of the knee should be followed by a lateral approach. It may also be helpful in second attempts to have a second operator compress the fluid from three sides of the knee. Ultrasonography should be performed if these two modalities are ineffective and if a septic joint is suspected. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Knee effusions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard approach to the hip requiring arthrocentesis remains performance of arthrocentesis under fluoroscopy, although ultrasound may be helpful for visualization of hip effusions, especially in adults. In patients thought to have a shoulder joint effusion, both the traditional anterior approach and the posterior approach should be attempted. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hip effusions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Shoulder effusions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28148/abstract/1\">",
"      Roberts WN, Hayes CW, Breitbach SA, Owen DS Jr. Dry taps and what to do about them: a pictorial essay on failed arthrocentesis of the knee. Am J Med 1996; 100:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28148/abstract/2\">",
"      Feller JF, Rishi M, Hughes EC. Lipoma arborescens of the knee: MR demonstration. AJR Am J Roentgenol 1994; 163:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28148/abstract/3\">",
"      Hardaker WT, Whipple TL, Bassett FH 3rd. Diagnosis and treatment of the plica syndrome of the knee. J Bone Joint Surg Am 1980; 62:221.",
"     </a>",
"    </li>",
"    <li>",
"     Schumacher HR Jr. Synovial fluid analysis and synovial biopsy. In: Textbook of Rheumatology, Kelly WN, Harris ED Jr, Ruddy S, Sledge CB (Eds), WB Saunders Company, Philadelphia 1993. p.562.",
"    </li>",
"    <li>",
"     Katz WA. Knees and legs. In: Diagnosis and Management of Rheumatic Diseases, 2nd, Katz WA (Ed), JB Lippincott, Philadelphia 1988. p.153.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28148/abstract/6\">",
"      Manger B, Kalden JR. Joint and connective tissue ultrasonography--a rheumatologic bedside procedure? A German experience. Arthritis Rheum 1995; 38:736.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7984 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28148=[""].join("\n");
var outline_f27_31_28148=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11369318\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES OF A DRY TAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dry tap in the knee",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dry tap in other joints",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      APPROACH TO THE PATIENT WITH A DRY TAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8656257\">",
"      Ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Knee effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hip effusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Shoulder effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11369318\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/7984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7984|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/21/336\" title=\"diagnostic image 1\">",
"      Mistaken Dx joint effusion MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?34/0/34831\" title=\"diagnostic image 2\">",
"      Dry tap medial fat pad MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/55/2933\" title=\"diagnostic image 3\">",
"      Lipoma arborescens MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/0/20480\" title=\"diagnostic image 4\">",
"      Medial plica of the knee MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/39/628\" title=\"diagnostic image 5\">",
"      Gelatinous effusion MRI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?2/24/2433\" title=\"diagnostic image 6\">",
"      Two causes for dry tap MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7984|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/1/22559\" title=\"figure 1\">",
"      Aspiration subtalar joint",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7984|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/12/16576\" title=\"picture 1\">",
"      Medial plica of the knee",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/7984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/18/5419\" title=\"table 1\">",
"      Causes of a dry tap",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/18/4392?source=related_link\">",
"      Musculoskeletal ultrasonography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44536?source=related_link\">",
"      Musculoskeletal ultrasonography: Guided injection and aspiration of joints and related structures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/60/1991?source=related_link\">",
"      Musculoskeletal ultrasonography: Nomenclature, technical considerations, validation, and standardization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_31_28149="Azathioprine: Patient drug information";
var content_f27_31_28149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Azathioprine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     see \"Azathioprine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=see_link\">",
"     see \"Azathioprine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Azasan&reg;;",
"     </li>",
"     <li>",
"      Imuran&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Azathioprine&reg;;",
"     </li>",
"     <li>",
"      Imuran&reg;;",
"     </li>",
"     <li>",
"      Mylan-Azathioprine;",
"     </li>",
"     <li>",
"      Teva-Azathioprine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-term use may raise the chance of cancer and unsafe infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026576\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep the body from harming the organ after an organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat diseases of the immune system.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691796",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Crohn's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691253",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take weeks to months to see the full effect in some diseases.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026575\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to azathioprine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697568",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Long-term use may raise your chance of cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697144",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a thiopurine methyltransferase deficiency, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count or low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698628",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026583\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Night sweats.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3424303",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Fever that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699556",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store tablets at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699319",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect tablets from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699478",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 2 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026585\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11092 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28149=[""].join("\n");
var outline_f27_31_28149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138216\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138217\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026574\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026576\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026575\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026580\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026581\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026583\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026578\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026579\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026584\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026585\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=related_link\">",
"      Azathioprine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/10/2216?source=related_link\">",
"      Azathioprine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_31_28150="Patch testing";
var content_f27_31_28150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Patch testing",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28150/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28150/contributors\">",
"     Bruce A Brod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28150/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28150/contributors\">",
"     Joseph Fowler, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28150/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28150/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/31/28150/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H26564771\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patch testing is an essential investigation to identify specific allergens in allergic contact dermatitis (ACD) or, in some cases, to make the diagnosis of ACD. Patch testing is based upon the principle that in sensitized individuals, primed antigen-specific T lymphocytes circulate throughout the body and are able to recreate a delayed type hypersensitivity reaction when non-irritating concentrations of the antigen are applied to normal skin.",
"   </p>",
"   <p>",
"    This topic will discuss indications, techniques, and interpretation of patch testing. The basic mechanisms, clinical manifestations, diagnosis, and management of ACD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7223?source=see_link\">",
"     \"Basic mechanisms and pathophysiology of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32758?source=see_link\">",
"     \"Management of allergic contact dermatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564778\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR PATCH TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for patch testing may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent eczematous eruptions when contact allergy is suspected [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Any chronic dermatitis, especially when involving the hands, feet, face, or eyelids.",
"     </li>",
"     <li>",
"      Eczematous dermatitis in individuals involved in high risk occupations for contact dermatitis (eg, health care workers, dental assistants, cosmetologists, machinists, or rubber and plastic workers).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patch testing also may be indicated when ACD is suspected as a complication of:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Atopic dermatitis",
"     </li>",
"     <li>",
"      Stasis dermatitis",
"     </li>",
"     <li>",
"      Seborrheic dermatitis",
"     </li>",
"     <li>",
"      Nummular eczema",
"     </li>",
"     <li>",
"      Asteatotic eczema",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564785\">",
"    <span class=\"h1\">",
"     SELECTION OF ALLERGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have identified more than 4350 chemicals as contact allergens with varying potential to cause ACD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/2\">",
"     2",
"    </a>",
"    ]. However, a high proportion of ACD are caused by a relatively small number of allergens commonly found in the environment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564792\">",
"    <span class=\"h2\">",
"     Standard series of allergens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard series of contact allergens, which are designed to include the most common sensitizers responsible for ACD in a given region, are recommended as the initial battery for patients undergoing patch testing. The standard series are revised on a regular basis, as new allergens are identified as a cause of ACD.",
"   </p>",
"   <p>",
"    There are several standard series throughout the world, including the North American standard series of approximately 70 allergens (determined by consensus of the North American Contact Dermatitis Group), and the European standard series of approximately 35 allergens (determined by consensus of the European Society of Contact Dermatitis and the European Environmental and Contact Dermatitis Research Group). Details on the standard series most commonly used can be found at",
"    <a class=\"external\" href=\"file://www.dermnetnz.org/dermatitis/standard-patch.html\">",
"     www.dermnetnz.org/dermatitis/standard-patch.html",
"    </a>",
"    . The American Contact Dermatitis Society (ACDS) (",
"    <a class=\"external\" href=\"file://www.contactderm.org/\">",
"     www.contactderm.org",
"    </a>",
"    ) has developed a recommended core series of 80 allergens divided into 8 panels.",
"   </p>",
"   <p>",
"    The thin-layer rapid-use epicutaneous (TRUE) test, which includes 29 allergens, is a commercially available ready-to-use test widely used in basic standard patch testing among dermatologists and allergists. Although it is easy to apply, it may have lower sensitivity than other standard series [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564799\">",
"    <span class=\"h2\">",
"     Additional series of patch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplemental series of patch tests suitable for specific exposures, including workplace exposures, are available to complement the standard series (eg, hairdressers, dental, or cosmetic series). The patient&rsquo;s clinical presentation and history help to determine whether testing with supplemental series",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    products provided by the patient is necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link&amp;anchor=H111504337#H111504337\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450433837\">",
"    <span class=\"h2\">",
"     Individualized patch testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the event that a standard series and supplemental series do not identify an offending antigen, patients may be patch tested with their own products. As a general rule, when patch testing patients with their own products, it is acceptable to use products that are left on the skin (eg, lotions, creams). However, products that typically are rinsed off the skin (eg, soap) should not be patch tested; when left on the skin these products may act as irritants. Rinse-off products may be tested with open testing. (See",
"    <a class=\"local\" href=\"#H26564820\">",
"     'Open test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Specific allergens can also be customized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450433945\">",
"    <span class=\"h1\">",
"     PATCH TEST PROCEDURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564806\">",
"    <span class=\"h2\">",
"     Preparing the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients need to be informed that patch testing is a time consuming process which requires at least three visits during a specified week. Patients should avoid showering, exercising, and extremes of heat and humidity, and should be alerted that positive reactions can result in itching and discomfort.",
"   </p>",
"   <p>",
"    Patch testing is usually performed on the back. If the back is excessively hairy it may be difficult to achieve adequate skin contact with the patches. To avoid irritation it is advisable to clip the hair from the back one or two days before patch testing.",
"   </p>",
"   <p>",
"    Potent topical corticosteroids applied to the test site or oral corticosteroids ideally should be discontinued at least two weeks before patch testing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Topical treatment with potent corticosteroids or systemic treatment with corticosteroids or other immunosuppressant drugs may cause weak or negative reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. Studies on poison ivy, which usually induces strong positive reactions, have indicated that it may be acceptable to perform patch testing with doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    up to 20 mg per day. However, this practice may be suboptimal for allergens that are weaker than poison ivy, and generally should be discouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oral antihistamines may be continued during patch testing as they have minimal if any effect on the mechanisms of delayed hypersensitivity. Since a positive patch test reaction is not a histamine mediated process, there is no pathophysiologic rationale to discontinue antihistamines prior to patch testing.",
"   </p>",
"   <p>",
"    Patients should avoid irradiation from both artificial and natural (sunlight) sources of ultraviolet (UV) radiation before patch testing. Irradiation with UVB can reduce the number of antigen presenting cells in the skin and the intensity of patch test reactions. Patch testing should be deferred in heavily tanned patients, and a minimum of four weeks after significant sun exposure should be allowed before patch testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450433884\">",
"    <span class=\"h2\">",
"     Patch test site",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal site for patch testing is the upper back. The outer aspect of the upper arms is an alternative. Placing patches on other skin areas may result in a higher degree of false-negative results. If the skin is oily, gentle degreasing can be performed with ethanol or another mild solvent.",
"   </p>",
"   <p>",
"    Patch testing should be performed on intact skin without dermatitis to minimize the risk of nonspecific inflammatory responses with numerous false positive tests (&ldquo;angry back&rdquo; syndrome). (See",
"    <a class=\"local\" href=\"#H2463532\">",
"     'The &ldquo;angry back&rdquo;'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450433919\">",
"    <span class=\"h2\">",
"     Types of tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2464091\">",
"    <span class=\"h3\">",
"     Closed test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly accepted technique for patch testing involves the application of test allergens under occlusion onto the skin of the upper back for two days. Allergens are applied in standard amounts to aluminum or synthetic material chambers mounted on non-occlusive tape strips. Commercially available patch test units are described in the table (",
"    <a class=\"graphic graphic_table graphicRef68134 \" href=\"UTD.htm?32/39/33404\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564820\">",
"    <span class=\"h3\">",
"     Open test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open test may be used to test products with a potential to create irritation on the skin, which include paints, soluble oils, soaps, glues, and other cleansing agents. Unlike traditional patch testing, the area is kept open. After 30 minutes the materials are gently removed and readings are performed in a delayed fashion similar to closed patch testing. If the reaction is negative but contact allergy is still suspected, closed patch testing with single ingredients in appropriate concentration and vehicle should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564827\">",
"    <span class=\"h3\">",
"     Semi-open test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The semi-open or semi-occlusive test is used for products with a slight irritant potential, including [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmaceutical products &ndash; Products containing antiseptic agents such as mercurial compounds (eg, phenylmercuriborate), quaternary ammonium salts such as benzalkonium chloride and iodine; antiseptics containing emulsifiers such as lauraminoxyde and nonoxynol; products containing solvents such as propylene glycol in high concentrations; creams based on the emulsifier sodium laurylsulfate.",
"     </li>",
"     <li>",
"      Cosmetic products &ndash; Products containing emulsifiers, solvents or other potentially irritant substances such as mascara, nail lacquers, hair dyes, shampoos, permanent-wave solutions, liquid soaps, and peels.",
"     </li>",
"     <li>",
"      Household and industrial products &ndash; Paints, resins, varnish, glue, ink, wax and soluble oils (after having verified that the pH is &gt;3 and &lt;11 or that a corrosive material is not involved).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For a semi-open test, minute amounts of allergens (1 to 2 microL) are applied to the skin and allowed to dry (water-soluble products can be tested as 1% or 2% solution). After complete drying, the test site is covered with a non-occlusive tape for two days and read at two and four days in a fashion similar to closed patch testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564834\">",
"    <span class=\"h3\">",
"     Repeated open application test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The repeated open application test (ROAT) may be useful to evaluate the clinical relevance of doubtful positive patch test reaction to preparations in which the putative allergen is present in a low concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ROAT is performed by applying 0.1 mL of the test substance to a specified area (antecubital fossa, outer aspect of the upper arm) twice daily for up to 28 days or until an eczematous reaction develops. A positive reaction may establish the clinical relevance of the product for the patient and confirm the source of the allergy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564841\">",
"    <span class=\"h3\">",
"     Usage test",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a closed patch test or open test is negative despite a history suggestive of ACE, the patient is asked to use the product under real world conditions. This method reproduces all the factors associated with the original dermatitis, for example sweating, friction or application of allergen on damaged or presensitized skin and is especially helpful in suspected clothing and cosmetic dermatitis. However, usage tests may fail to differentiate irritative from allergic dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454486017\">",
"    <span class=\"h2\">",
"     Patch test reading",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454485967\">",
"    <span class=\"h3\">",
"     Initial reading",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patches typically are left in place for a period of two days (48 hours), which allows adequate penetration of the allergen into the skin. To reduce the number of false positive readings, the initial evaluation is generally performed between 15 and 60 minutes after the patches are removed, when the transient erythema has resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H454485974\">",
"    <span class=\"h3\">",
"     Second reading",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second reading is critically important to distinguish irritant reactions (which fade) from true allergic reactions (which persist) and to identify allergic reactions that do not appear at the time of patch removal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/14\">",
"     14",
"    </a>",
"    ]. The time of the second reading varies among different patch testing centers, but generally is on day four or five. Day four readings appear to be associated with a low number of false negative reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/15\">",
"     15",
"    </a>",
"    ]. Performing the second reading too soon may miss some delayed reactions, whereas performing the second reading too late may result in missing some positive reactions that fade rapidly, such as those due to fragrances. An additional reading at day six or seven may be useful to identify a small number of late, positive reactions, in particular to nickel,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    , and corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/16\">",
"     16",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564848\">",
"    <span class=\"h1\">",
"     PATCH TEST INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correct",
"    <strong>",
"    </strong>",
"    reading and interpretation of patch test reactions require the skills of a trained clinician. The International Contact Dermatitis Research Group has developed a scoring system for evaluating patch test reactions that has been accepted by the North American Contact Dermatitis Group (",
"    <a class=\"graphic graphic_table graphicRef65159 \" href=\"UTD.htm?34/17/35099\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strong positive allergic reactions are erythematous and infiltrated, often with minute papules or vesicles that may coalesce into bullae (",
"    <a class=\"graphic graphic_picture graphicRef76954 graphicRef74380 \" href=\"UTD.htm?12/37/12884\">",
"     picture 1A-B",
"    </a>",
"    ). The reaction may extend beyond the margins of the patch and is usually associated with pruritus. In all cases, positive reactions should be evaluated within the clinical context to establish their relevance. (See",
"    <a class=\"local\" href=\"#H2463470\">",
"     'Determining the clinical relevance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It may be difficult to distinguish true positive weak reactions from irritant reactions. In addition, a variety of morphologic patterns can be seen in irritant patch test reactions, depending upon the nature",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concentration of irritants (",
"    <a class=\"graphic graphic_table graphicRef57968 \" href=\"UTD.htm?14/61/15323\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2463470\">",
"    <span class=\"h1\">",
"     DETERMINING THE CLINICAL RELEVANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relevance of a positive reaction in the diagnosis of ACD is established by examining the patient&rsquo;s clinical manifestations and history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link&amp;anchor=H1646554#H1646554\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In many cases, relevance to the current problem can be clearly established and avoidance advice given. In some cases the relevance is found to a past episode or may be uncertain. Some individuals may have a positive patch test reaction but still tolerate the contact with the allergen.",
"   </p>",
"   <p>",
"    If the relevance of the positive patch test is not easily apparent, it is important to reexamine in greater detail the history of exposure to the allergen or cross-reacting substances, and evaluate the outcome after the patient avoids the allergen.",
"   </p>",
"   <p>",
"    A detailed exposure history must include occupational exposure, hobbies, personal care products, topical medications, and protective measures (",
"    <a class=\"graphic graphic_table graphicRef65321 \" href=\"UTD.htm?10/43/10939\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=see_link&amp;anchor=H111504337#H111504337\">",
"     \"Clinical features and diagnosis of allergic contact dermatitis\", section on 'History'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some cases of occupational ACD, history must be supplemented with a detailed environmental evaluation. This might include a workplace visit, assessment of materials contacted in the workplace, evaluation of the physicochemical properties of a substance, and evaluating the exposure parameters. The exposure parameters include the route and site of exposure, dose, duration, frequency, and surrounding environmental conditions.",
"   </p>",
"   <p>",
"    Sometimes provocation with the allergen in the form of a usage test or repeated open application test (ROAT) may be required to determine the clinical relevance. (See",
"    <a class=\"local\" href=\"#H26564841\">",
"     'Usage test'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26564834\">",
"     'Repeated open application test'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no consensus regarding the definition, scoring, and determination of clinical relevance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. One set of criteria for scoring clinical relevance is provided in the table (",
"    <a class=\"graphic graphic_table graphicRef71193 \" href=\"UTD.htm?6/10/6315\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/21\">",
"     21",
"    </a>",
"    ]. The most reliable \"test\" of relevance is the finding of clearance of the dermatitis with avoidance of identified allergens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26564869\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF PATCH TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although generally safe, patch testing may cause adverse reactions that are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72682 \" href=\"UTD.htm?17/29/17884\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2463525\">",
"    <span class=\"h2\">",
"     Active sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patch testing is associated with a small risk of sensitization. A late reaction appearing 10 to 20 days after the test may indicate active sensitization from the patch test, although some \"normal\" patch test reactions may be observed at this late time. However, the risk of active sensitization from patch testing appears to be very low [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/22-26\">",
"     22-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2463532\">",
"    <span class=\"h2\">",
"     The &ldquo;angry back&rdquo;",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;angry back&rdquo; or &ldquo;excited skin syndrome&rdquo; occurs when a few strong positive reactions cause a chain of multiple reactions to other patch tests that would otherwise be negative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/27\">",
"     27",
"    </a>",
"    ]. In most cases, one or two strong reactions create an array of false positive reactions. The cause of this phenomenon is not known. One hypothesis is that some individuals who have an active dermatitis at other body sites or exhibit a strong patch test reaction develop a nonspecific hyperreactivity of the skin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/27\">",
"     27",
"    </a>",
"    ]. Another hypothesis is that placing substances with a similar chemical affinity in the same area induces multiple positive reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28150/abstract/28\">",
"     28",
"    </a>",
"    ]. Patients with the &ldquo;angry back&rdquo; should be retested with the positive allergens separately and sequentially. Additional validation of positive reactions can be performed by using repeated open application tests. (See",
"    <a class=\"local\" href=\"#H26564834\">",
"     'Repeated open application test'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33965340\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patch testing is an essential investigation to identify specific allergens in allergic contact dermatitis (ACD). (See",
"      <a class=\"local\" href=\"#H26564771\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for patch testing include persistent eczematous dermatitis; chronic dermatitis, especially of the hands, feet, face, or eyelids; eczematous dermatitis in individuals in high risk occupations; suspicion of ACD as a complication of other forms of dermatitis. (See",
"      <a class=\"local\" href=\"#H26564778\">",
"       'Indications for patch testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Standard series of contact allergens, which are designed to include the most common sensitizers responsible for ACD in a given region, are recommended as the initial battery for patients undergoing patch testing. Additional series may be used to complement the standard series (eg, hairdressers, dental, or cosmetic series). (See",
"      <a class=\"local\" href=\"#H26564785\">",
"       'Selection of allergens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most commonly accepted technique for patch testing involves the application of test allergens to the skin of the upper back under occlusion for two days (closed test). Alternative methods, including open or usage tests, may be useful for irritant allergens, pharmaceutical products, or cosmetics. (See",
"      <a class=\"local\" href=\"#H450433919\">",
"       'Types of tests'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Correct",
"      <strong>",
"      </strong>",
"      reading and interpretation of patch test reactions require the skills of a trained clinician (",
"      <a class=\"graphic graphic_table graphicRef65159 \" href=\"UTD.htm?34/17/35099\">",
"       table 2",
"      </a>",
"      ). Strong positive reactions are erythematous and infiltrated, often with minute papules or vesicles (",
"      <a class=\"graphic graphic_picture graphicRef76954 graphicRef74380 \" href=\"UTD.htm?12/37/12884\">",
"       picture 1A-B",
"      </a>",
"      ). It may be difficult to distinguish true positive weak reactions from irritant reactions (",
"      <a class=\"graphic graphic_table graphicRef57968 \" href=\"UTD.htm?14/61/15323\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26564848\">",
"       'Patch test interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical relevance of a positive patch test is established by reexamining the patient&rsquo;s clinical manifestations and history. (See",
"      <a class=\"local\" href=\"#H26564848\">",
"       'Patch test interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/1\">",
"      Bourke J, Coulson I, English J, British Association of Dermatologists Therapy Guidelines and Audit Subcommittee. Guidelines for the management of contact dermatitis: an update. Br J Dermatol 2009; 160:946.",
"     </a>",
"    </li>",
"    <li>",
"     Carol, LY, Taylor, JS.  Contact Dermatitis and Related Disorders. ACP Medicine. Dale, DC, Federmann, DD, Eds. BC Decker Inc, Hamilton, ON, September 2008 file://www.acpmedicine.com (accessed August 6, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/3\">",
"      Cohen DE, Brancaccio R, Andersen D, Belsito DV. Utility of a standard allergen series alone in the evaluation of allergic contact dermatitis: a retrospective study of 732 patients. J Am Acad Dermatol 1997; 36:914.",
"     </a>",
"    </li>",
"    <li>",
"     Dooms-Goossens A. Patch testing without a kit. In: Practical contact dermatitis: A handbook for the practitioner, Guin JD (Ed), McGraw-Hill Inc., New York 1995. p.63.",
"    </li>",
"    <li>",
"     deGroot AC, Frosch PJ. Patch test concentrations and vehicles for testing contact allergens. In: Contact Dermatitis, 3rd ed, Frosch PJ, Menne T, Lepooittevin JP (Eds), Springer, Berlin 2006. p.907.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/6\">",
"      Sukanto H, Nater JP, Bleumink E. Influence of topically applied corticosteroids on patch test reactions. Contact Dermatitis 1981; 7:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/7\">",
"      Anveden I, Lindberg M, Andersen KE, et al. Oral prednisone suppresses allergic but not irritant patch test reactions in individuals hypersensitive to nickel. Contact Dermatitis 2004; 50:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/8\">",
"      O'Quinn SE, Isbell KH. Influence of oral prednisone on eczematous patch test reactions. Arch Dermatol 1969; 99:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/9\">",
"      Condie MW, Adams RM. Influence of oral prednisone on patch-test reactions to Rhus antigen. Arch Dermatol 1973; 107:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/10\">",
"      Goossens A. Recognizing and testing allergens. Dermatol Clin 2009; 27:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/11\">",
"      Goossens A. Art and science of patch testing. Indian J Dermatol Venereol Leprol 2007; 73:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/12\">",
"      Hannuksela M, Salo H. The repeated open application test (ROAT). Contact Dermatitis 1986; 14:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/13\">",
"      Villarama CD, Maibach HI. Correlations of patch test reactivity and the repeated open application test (ROAT)/provocative use test (PUT). Food Chem Toxicol 2004; 42:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/14\">",
"      Uter WJ, Geier J, Schnuch A. Good clinical practice in patch testing: readings beyond day 2 are necessary: a confirmatory analysis. Members of the Information Network of Departments of Dermatology. Am J Contact Dermat 1996; 7:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/15\">",
"      Todd DJ, Handley J, Metwali M, et al. Day 4 is better than day 3 for a single patch test reading. Contact Dermatitis 1996; 34:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/16\">",
"      Jonker MJ, Bruynzeel DP. The outcome of an additional patch-test reading on days 6 or 7. Contact Dermatitis 2000; 42:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/17\">",
"      Wilkinson DS, Fregert S, Magnusson B, et al. Terminology of contact dermatitis. Acta Derm Venereol 1970; 50:287.",
"     </a>",
"    </li>",
"    <li>",
"     Foussereau J, Benezra C, Maibach HI. Occupational contact dermatitis. Clinical and chemical aspects, Munksgaard, Copenhagen 1982. Vol 26.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/19\">",
"      Lachapelle JM. A proposed relevance scoring system for positive allergic patch test reactions: practical implications and limitations. Contact Dermatitis 1997; 36:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/20\">",
"      Marks JG, Belsito DV, DeLeo VA, et al. North American Contact Dermatitis Group patch test results for the detection of delayed-type hypersensitivity to topical allergens. J Am Acad Dermatol 1998; 38:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/21\">",
"      Jacob SE, Brod B, Crawford GH. Clinically relevant patch test reactions in children--a United States based study. Pediatr Dermatol 2008; 25:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/22\">",
"      Jensen CD, Paulsen E, Andersen KE. Retrospective evaluation of the consequence of alleged patch test sensitization. Contact Dermatitis 2006; 55:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/23\">",
"      Thyssen JP, Menn&eacute; T, Nielsen NH, Linneberg A. Is there a risk of active sensitization to PPD by patch testing the general population? Contact Dermatitis 2007; 57:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/24\">",
"      Uter W, Hillen U, Geier J, et al. Is incident sensitization to p-phenylenediamine related to particular exposure patterns? Results of a questionnaire study. Contact Dermatitis 2007; 56:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/25\">",
"      Devos SA, Van Der Valk PG. The risk of active sensitization to PPD. Contact Dermatitis 2001; 44:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/26\">",
"      Dawe SA, White IR, Rycroft RJ, et al. Active sensitization to para-phenylenediamine and its relevance: a 10-year review. Contact Dermatitis 2004; 51:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/27\">",
"      Mitchell JC. The angry back syndrome: eczema creates eczema. Contact Dermatitis 1975; 1:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28150/abstract/28\">",
"      Duarte I, Lazzarini R. Excited skin syndrome associated with patch-test application technique. Dermatitis 2006; 17:161.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16691 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28150=[""].join("\n");
var outline_f27_31_28150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33965340\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26564771\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26564778\">",
"      INDICATIONS FOR PATCH TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26564785\">",
"      SELECTION OF ALLERGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26564792\">",
"      Standard series of allergens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26564799\">",
"      Additional series of patch testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450433837\">",
"      Individualized patch testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450433945\">",
"      PATCH TEST PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26564806\">",
"      Preparing the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450433884\">",
"      Patch test site",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450433919\">",
"      Types of tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2464091\">",
"      - Closed test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26564820\">",
"      - Open test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26564827\">",
"      - Semi-open test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26564834\">",
"      - Repeated open application test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26564841\">",
"      - Usage test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H454486017\">",
"      Patch test reading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H454485967\">",
"      - Initial reading",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H454485974\">",
"      - Second reading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26564848\">",
"      PATCH TEST INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2463470\">",
"      DETERMINING THE CLINICAL RELEVANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26564869\">",
"      COMPLICATIONS OF PATCH TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2463525\">",
"      Active sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2463532\">",
"      The &ldquo;angry back&rdquo;",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33965340\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16691|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/61/22480\" title=\"picture 1A\">",
"      Positive patch test reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/5/21599\" title=\"picture 1B\">",
"      Positive patch test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/39/33404\" title=\"table 1\">",
"      Patch test units",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/17/35099\" title=\"table 2\">",
"      Patch test interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/61/15323\" title=\"table 3\">",
"      Irritant patch test reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10939\" title=\"table 4\">",
"      History taking in ACD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/10/6315\" title=\"table 5\">",
"      Patch test relevance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/29/17884\" title=\"table 6\">",
"      Adverse reactions to patch testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/3/7223?source=related_link\">",
"      Basic mechanisms and pathophysiology of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/42/11943?source=related_link\">",
"      Clinical features and diagnosis of allergic contact dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/63/32758?source=related_link\">",
"      Management of allergic contact dermatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_31_28151="Etanercept: Drug information";
var content_f27_31_28151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Etanercept: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/34/36389?source=see_link\">",
"    see \"Etanercept: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32790?source=see_link\">",
"    see \"Etanercept: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F6655343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F167887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Enbrel&reg;;",
"     </li>",
"     <li>",
"      Enbrel&reg; SureClick&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F167888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Enbrel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F167912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Tumor Necrosis Factor (TNF) Blocking Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F167891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Once-weekly dosing:",
"     </i>",
"     50 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Twice-weekly dosing:",
"     </i>",
"     25 mg given twice weekly (individual doses should be separated by 72-96 hours)",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Plaque psoriasis:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial: 50 mg twice weekly, 72-96 hours apart; maintain initial dose for 3 months (starting doses of 25 or 50 mg once weekly have also been used successfully)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maintenance dose: 50 mg once weekly",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F167901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32790?source=see_link\">",
"      see \"Etanercept: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Juvenile idiopathic arthritis:",
"     </b>",
"     Children 2-17 years: SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Once-weekly dosing:",
"     </i>",
"     0.8 mg/kg (maximum: 50 mg/dose) once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Twice-weekly dosing:",
"     </i>",
"     0.4 mg/kg (maximum: 25 mg/dose) twice weekly (individual doses should be separated by 72-96 hours)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F167892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     SubQ: Refer to adult dosing. Although greater sensitivity of some elderly patients cannot be ruled out, no overall differences in safety or effectiveness were observed.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14471443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14471444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F167868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enbrel&reg;: 25 mg [contains benzyl alcohol (in diluent), sucrose 10 mg; derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enbrel&reg;: 50 mg/mL (0.51 mL, 0.98 mL) [contains natural rubber/natural latex in packaging, sucrose 1%; derived from or manufactured using Chinese hamster ovary cells; prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Enbrel&reg; SureClick&reg;: 50 mg/mL (0.98 mL) [contains natural rubber/natural latex in packaging, sucrose 1%; derived from or manufactured using Chinese hamster ovary cells; autoinjector]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F167854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088590.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088590.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F167870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer subcutaneously. Rotate injection sites. New injections should be given at least one inch from an old site and never into areas where the skin is tender, bruised, red, or hard.",
"     <b>",
"      Note:",
"     </b>",
"     If the physician determines that it is appropriate, patients may self-inject after proper training in injection technique.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for reconstitution: Follow package instructions carefully for reconstitution. The maximum amount injected at any single site should not exceed 25 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution for injection: May be allowed to reach room temperature prior to injection.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F167869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of moderately- to severely-active rheumatoid arthritis (RA); moderately- to severely-active polyarticular juvenile idiopathic arthritis (JIA); psoriatic arthritis; active ankylosing spondylitis (AS); moderate-to-severe chronic plaque psoriasis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7914269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Enbrel&reg; may be confused with Levbid&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F167910\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (17% to 19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (3% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (5%; children 19%), diarrhea (3% to 16%), vomiting (3%; children 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (14% to 43%; bleeding, bruising, erythema, itching, pain, or swelling)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Respiratory tract infection (21% to 54%; upper: 38% to 65%), rhinitis (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Infection (50% to 81%; children 62%), positive antidouble-stranded DNA antibodies (15% by RIA, 3% by",
"     <i>",
"      Crithidia luciliae",
"     </i>",
"     assay), positive ANA (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &ge;3% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (7%), fever (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (2% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (children 9%), dyspepsia (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis (7%), cough (6%), respiratory disorder (5%), sinusitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;3% (Limited to important or life-threatening): Abscess, adenopathy, allergic reactions, anemia, angioedema, anorexia, aplastic anemia, appendicitis, aseptic meningitis, aspergillosis, bursitis, cerebral ischemia, cholecystitis, coagulopathy, cutaneous ulcer, deep vein thrombosis, demyelinating CNS disorders (suggestive of multiple sclerosis, transverse myelitis, or optic neuritis), depression, erythema multiforme, esophagitis, gastritis, gastroenteritis, gastrointestinal hemorrhage, heart failure, hepatitis (autoimmune), herpes zoster, hydrocephalus (with normal pressure), hyper-/hypotension, hypersensitivity, inflammatory bowel disease, interstitial lung disease, intestinal perforation, leukemias, leukopenia, lupus erythematous (cutaneous), lupus-like syndrome, lymphadenopathy, lymphomas, malignancies, melanoma, membranous glomerulopathy, Merkel cell carcinoma, MI, mouth ulcer, multiple sclerosis, myocardial ischemia, neutropenia, nonmelanoma skin cancer, optic neuritis, pancreatitis, pancytopenia,",
"     <i>",
"      Pneumocystis jiroveci",
"     </i>",
"     pneumonia, polymyositis, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pulmonary disease, pulmonary embolism, renal calculus, sarcoidosis, scleritis, seizure, stroke, Stevens-Johnson syndrome, subcutaneous nodules, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, tuberculosis, tuberculous arthritis, urinary tract infection, uveitis, varicella infection, vasculitis (cutaneous and systemic), weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F167873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to etanercept or any component of the formulation; patients with sepsis (mortality may be increased)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F167858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Allergic reactions may occur, if an anaphylactic reaction or other serious allergic reaction occurs, administration should be discontinued immediately and appropriate therapy initiated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disorder: Positive antinuclear antibody titers have been detected in patients (with negative baselines). Rare cases of autoimmune disorder, including lupus-like syndrome or autoimmune hepatitis, have been reported; monitor and discontinue if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: Rare reactivation of hepatitis B (HBV) has occurred in chronic carriers of the virus, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients. Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Patients receiving etanercept are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving TNF-blocking agents, including etanercept. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.",
"     </b>",
"     Caution should be exercised when considering use in the elderly or in patients with conditions that predispose them to infections (eg, diabetes) or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis), or with latent or localized infections. Do not initiate etanercept therapy with clinically important active infection. Patients who develop a new infection while undergoing treatment should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Lymphoma and other malignancies have been reported in children and adolescent patients receiving TNF-blocking agents, including etanercept.",
"     </b>",
"     Half of the malignancies reported in children were lymphomas (Hodgkin&rsquo;s and non-Hodgkin&rsquo;s) while other cases varied and included malignancies not typically observed in this population. The impact of etanercept on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving etanercept. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn&rsquo;s disease or ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis:",
"     <b>",
"      [U.S. Boxed Warning]: Tuberculosis (disseminated or extrapulmonary) has been reported in patients receiving etanercept; both reactivation of latent infection and new infections have been reported.",
"     </b>",
"     Patients should be evaluated for tuberculosis risk factors and for latent tuberculosis infection with a tuberculin skin test prior to starting therapy. Treatment of latent tuberculosis should be initiated before etanercept therapy; consider antituberculosis treatment if adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or with risk factors despite negative skin test. Some patients who tested negative prior to therapy have developed active infection; monitor for signs and symptoms of tuberculosis in all patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Alcoholic hepatitis: Use with caution in patients with moderate to severe alcoholic hepatitis. Compared to placebo, the mortality rate in patients treated with etanercept was similar at one month but significantly higher after 6 months.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Demyelinating CNS disease: Use with caution in patients with pre-existing or recent onset CNS demyelinating disorders; rare cases of new onset or exacerbation of CNS demyelinating disorders have occurred; may present with mental status changes and some may be associated with permanent disability. Optic neuritis, transverse myelitis, multiple sclerosis, and new onset or exacerbation of seizures have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with heart failure or decreased left ventricular function; worsening and new-onset heart failure has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic disorders: Use with caution in patients with a history of significant hematologic abnormalities; has been associated with pancytopenia and aplastic anemia (rare cases in postmarketing experience). Patients must be advised to seek medical attention if they develop signs and symptoms suggestive of blood dyscrasias; discontinue if significant hematologic abnormalities are confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Wegener's granulomatosis: Use is not recommended in patients with Wegener's granulomatosis who are receiving immunosuppressive therapy due to higher incidence of noncutaneous solid malignancies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anakinra: Due to a higher incidence of serious infections, concomitant use with anakinra is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Varicella virus exposure: Patients with a significant exposure to varicella virus should temporarily discontinue therapy; treatment with varicella zoster immune globulin should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some dosage forms may contain benzyl alcohol which has been associated with &ldquo;gasping syndrome&rdquo; in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Some dosage forms may contain dry natural rubber (latex).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F167863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Etanercept may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclophosphamide: Etanercept may enhance the adverse/toxic effect of Cyclophosphamide. An increased risk of solid cancer development may be present.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F4028835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Echinacea may decrease the therapeutic effects of etanercept (avoid concurrent use).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F167865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F167876\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Developmental toxicity studies performed in animals have revealed no evidence of harm to the fetus. There are no studies in pregnant women; this drug should be used during pregnancy only if clearly needed. A pregnancy registry has been established to monitor outcomes of women exposed to etanercept during pregnancy (877-311-8972).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F167894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F167877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether etanercept is excreted in human milk. Because many drugs and immunoglobulins are excreted in human milk and the potential for serious adverse reactions exists, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F167875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Kit",
"     </b>",
"     (Enbrel Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (1): $331.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Enbrel Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/0.5 mL (0.51 mL): $331.63",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (0.98 mL): $663.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Enbrel SureClick Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (0.98 mL): $663.26",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6045563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor improvement of symptoms and physical function assessments.  Latent TB screening prior to initiating and during therapy; signs/symptoms of infection (prior to, during, and following therapy); CBC with differential; signs/symptoms/worsening of heart failure; HBV screening prior to initiating (all patients), HBV carriers (during and for several months following therapy); signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss).",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F167878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Enbrel (AR, AT, AU, BE, BG, BR, CH, CL, CN, CO, CR, CZ, DE, DK, EC, EE, ES, FI, FR, GB, GR, GT, HK, HN, ID, IE, IL, IN, IT, KP, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PT, RU, SE, SG, SK, SV, TH, TR, TW, VE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F167857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Etanercept is a recombinant DNA-derived protein composed of tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. Etanercept binds tumor necrosis factor (TNF) and blocks its interaction with cell surface receptors. TNF plays an important role in the inflammatory processes and the resulting joint pathology of rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), and plaque psoriasis.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F167872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~2-3 weeks; RA: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: RA: SubQ: 72-132 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: RA: SubQ: 35-103 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Breedveld F, &ldquo;New Tumor Necrosis Factor-Alpha Biologic Therapies for Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Eur Cytokine Netw",
"      </i>",
"      , 1998, 9(3):233-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/9831171/pubmed\" id=\"9831171\" target=\"_blank\">",
"        9831171",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Data on file, Immunex Corporation.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Feldmann M, Brennan FM, and Maini RN, &ldquo;Role of Cytokines in Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Annu Rev Immunol",
"      </i>",
"      , 1996, 14:397-440.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/8717520/pubmed\" id=\"8717520\" target=\"_blank\">",
"        8717520",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Felson DT, Anderson JJ, Boers M, et al, &ldquo;American College of Rheumatology. Preliminary Definition of Improvement in Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1995, 38(6):727-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/7779114/pubmed\" id=\"7779114\" target=\"_blank\">",
"        7779114",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fisher CJ Jr, Agosti JM, Opal SM, et al, &ldquo;Treatment of Septic Shock With the Tumor Necrosis Factor Receptor:Fc Fusion Protein. The Soluble TNF Receptor Sepsis Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 334(26):1697-702.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/8637514/pubmed\" id=\"8637514\" target=\"_blank\">",
"        8637514",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Giannini EH, Ruperto N, Ravelli A, et al, &ldquo;Preliminary Definition of Improvement in Juvenile Arthritis,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1997, 40(7):1202-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/9214419/pubmed\" id=\"9214419\" target=\"_blank\">",
"        9214419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(9): 898-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/22948700/pubmed\" id=\"22948700\" target=\"_blank\">",
"        22948700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lovell DJ, Giannini EH, Reiff A, et al, &ldquo;Etanercept in Children With Polyarticular Juvenile Rheumatoid Arthritis: Pediatric Rheumatology Collaborative Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 342(11):763-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/10717011/pubmed\" id=\"10717011\" target=\"_blank\">",
"        10717011",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lovell DJ, Giannini EH, Reiff A, et al, &ldquo;Long-Term Efficacy and Safety of Etanercept in Children With Polyarticular-Course Juvenile Rheumatoid Arthritis: Interim Results From an Ongoing Multicenter, Open-Label, Extended-Treatment Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2003, 48(1):218-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/12528122/pubmed\" id=\"12528122\" target=\"_blank\">",
"        12528122",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mease PJ, Goffe BS, Metz J, et al, &ldquo;Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 356(9227):385-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/10972371/pubmed\" id=\"10972371\" target=\"_blank\">",
"        10972371",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moreland LW, Baumgartner SW, Schiff MH, et al, &ldquo;Treatment of Rheumatoid Arthritis With a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1997, 337(3):141-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/9219699/pubmed\" id=\"9219699\" target=\"_blank\">",
"        9219699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;New Drugs for Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1998, 40(1040):110-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/9844625/pubmed\" id=\"9844625\" target=\"_blank\">",
"        9844625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Parakkal D, Sifuentes H, Semer R, et al, &ldquo;Hepatosplenic T-Cell Lymphoma in Patients Receiving TNF-&alpha; Inhibitor Therapy: Expanding the Groups at Risk,&rdquo;",
"      <i>",
"       Eur J Gastroenterol Hepatol",
"      </i>",
"      , 2011, 23(12):1150-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/21941193/pubmed\" id=\"21941193\" target=\"_blank\">",
"        21941193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ramey DR, Fries JF, and Singh G, &ldquo;The Health Assessment Questionnaire 1995 - Status and Review,&rdquo; Spilker B, ed,",
"      <i>",
"       Quality of Life and Pharmacoeconomics in Clinical Trials",
"      </i>",
"      , 2nd ed, Philadelphia, PA: Lippincott-Raven, 1996.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saxne T, Palladino MA Jr, Heinegard D, et al, &ldquo;Detection of Tumor Necrosis Factor Alpha but Not Tumor Necrosis Factor Beta in Rheumatoid Arthritis Synovial Fluid and Serum,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 1988, 31(8):1041-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/3136775/pubmed\" id=\"3136775\" target=\"_blank\">",
"        3136775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith CA, Farrah T, and Goodwin RG, &ldquo;The TNF Receptor Superfamily of Cellular and Viral Proteins: Activation, Costimulation, and Death,&rdquo;",
"      <i>",
"       Cell",
"      </i>",
"      , 1994, 76(6):959-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/8137429/pubmed\" id=\"8137429\" target=\"_blank\">",
"        8137429",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Oosten BW, Barkhof F, Truyen L, et al, &ldquo;Increased MRI Activity and Immune Activation in Two Multiple Sclerosis Patients Treated With the Monoclonal Anti-tumor Necrosis Factor Antibody cA2,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1996, 47(6):1531-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/8960740/pubmed\" id=\"8960740\" target=\"_blank\">",
"        8960740",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weinblatt ME, Kremer JM, Bankhurst AD, et al, &ldquo;A Trial of Etanercept, A Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients With Rheumatoid Arthritis Receiving Methotrexate,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 340(4):253-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/9920948/pubmed\" id=\"9920948\" target=\"_blank\">",
"        9920948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wooley PH, Dutcher J, Widmer MB, et al, &ldquo;Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice,&rdquo;",
"      <i>",
"       J Immunol",
"      </i>",
"      , 1993, 151(11):6602-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/31/28151/abstract-text/8245488/pubmed\" id=\"8245488\" target=\"_blank\">",
"        8245488",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8925 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28151=[""].join("\n");
var outline_f27_31_28151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6655343\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167887\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167888\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167912\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167891\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167901\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167892\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471443\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471444\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167868\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167854\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874648\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167870\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167869\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7914269\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167910\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167873\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167858\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299288\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167863\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4028835\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167865\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167876\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167894\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167877\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167875\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6045563\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167878\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167857\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F167872\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8925|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/34/36389?source=related_link\">",
"      Etanercept: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/1/32790?source=related_link\">",
"      Etanercept: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_31_28152="Retrograde urethrogram with short stricture";
var content_f27_31_28152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57667%7ESURG%2F75050%7ESURG%2F72649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57667%7ESURG%2F75050%7ESURG%2F72649&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Retrograde urethrogram with short stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Retrograde urethrogram with moderate stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Retrograde urethrogram with severe stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 418px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28152=[""].join("\n");
var outline_f27_31_28152=null;
var title_f27_31_28153="Chronic peritoneal dialysis in children";
var content_f27_31_28153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic peritoneal dialysis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28153/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28153/contributors\">",
"     Annabelle Chua, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28153/contributors\">",
"     Bradley A Warady, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28153/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28153/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/31/28153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/31/28153/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/31/28153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15616673\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic peritoneal dialysis (CPD) is the most common dialysis treatment modality used to treat pediatric patients with end-stage renal disease (ESRD), particularly in children less than five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. CPD offers several advantages over hemodialysis (HD) that are beneficial for children; however, there are clinical settings in which CPD is contraindicated or may not be the best dialytic modality. In addition, although the principles of CPD are the same for pediatric and adult patients, there are aspects of CPD that are unique to children and infants, which need to be addressed to ensure the adequacy of dialysis and to reduce complications for the pediatric patient.",
"   </p>",
"   <p>",
"    The various aspects of chronic peritoneal dialysis in children will be reviewed here. Overview of renal replacement therapy in children and hemodialysis for children with chronic kidney disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link\">",
"     \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link\">",
"     \"Hemodialysis for children with chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general mechanisms of the removal of solute and fluid during CPD are the same in the adult and pediatric patient and are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=see_link\">",
"     \"Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3926445\">",
"    <span class=\"h1\">",
"     PERITONEAL DIALYSIS VERSUS HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have not been any comparative studies of peritoneal dialysis (PD) and hemodialysis (HD) outcomes in children with end-stage renal disease (ESRD) to suggest superiority of one procedure versus the other. While the majority of pediatric patients with ESRD who require dialysis can be managed with chronic peritoneal dialysis (CPD), the choice of dialysis modality is most often based on patient and family preference, center philosophy, and availability of the desired modality.",
"   </p>",
"   <p>",
"    The quality of life for both patient and family assumes great importance in the selection of home dialysis therapy as a result of the &ldquo;burden of care&rdquo; associated with this approach to ESRD management. As such, careful evaluation of the family&rsquo;s social, psychological, and economic background, ideally by a multiprofessional team including the family physician and nephrologist, dialysis nurse, psychologist, and social worker, is mandatory if a fully informed decision regarding modality selection is to be made [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although both HD and PD are effective in solute and fluid removal, CPD offers the following advantages over HD in children [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less restricted diet including fluid intake because CPD is performed daily. This is particularly beneficial for infants in whom nutritional intake is exclusively or mainly dependent upon a liquid diet.",
"     </li>",
"     <li>",
"      Therapy is performed at home, thereby allowing for regular school attendance and participation in other normal childhood activities. For those who live a long distance from a hemodialysis center, there is no need to travel to the unit three or more times per week for dialysis treatments.",
"     </li>",
"     <li>",
"      No vascular access and the associated need for repeated venipuncture (arteriovenous",
"      <span class=\"nowrap\">",
"       fistula/graft)",
"      </span>",
"      or the risk for bacteremia (central venous catheter). In particular, vascular access for hemodialysis is challenging in patients less than two years of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link&amp;anchor=H6760051#H6760051\">",
"       \"Hemodialysis for children with chronic kidney disease\", section on 'Vascular access'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disadvantages of CPD include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased caregiver burden, which may lead to psychological and social stress [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Possible",
"      <span class=\"nowrap\">",
"       patient/caregiver",
"      </span>",
"      nonadherence to prescribed therapy",
"     </li>",
"     <li>",
"      Risk of CPD related infections, such as catheter",
"      <span class=\"nowrap\">",
"       exit-site/tunnel",
"      </span>",
"      infections and peritonitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616680\">",
"    <span class=\"h2\">",
"     Contraindications to CPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only absolute contraindications to CPD include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Omphalocele",
"     </li>",
"     <li>",
"      Gastroschisis",
"     </li>",
"     <li>",
"      Bladder exstrophy",
"     </li>",
"     <li>",
"      Diaphragmatic hernia",
"     </li>",
"     <li>",
"      Obliterated peritoneal cavity and peritoneal membrane failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications to CPD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impending abdominal surgery",
"     </li>",
"     <li>",
"      Impending (&lt;3 months) living-related kidney transplantation",
"     </li>",
"     <li>",
"      Lack of an appropriate caregiver for home therapy",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Patient/caregiver",
"      </span>",
"      choice for hemodialysis, which is available and medically suitable",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Controversy exists as to whether the presence of a ventriculoperitoneal shunt constitutes a contraindication to CPD. Limited experience suggests that PD is acceptable in this situation, if no feasible alternative dialysis option exists, recognizing the potential infection related risks.",
"   </p>",
"   <p>",
"    On the other hand, the presence of a colostomy, gastrostomy, ureterostomy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pyelostomy does not preclude CPD. Patients with prune-belly syndrome have also been successfully managed with CPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616702\">",
"    <span class=\"h1\">",
"     PRESCRIBING PERITONEAL DIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of the peritoneal dialysis (PD) modality and the specific prescription components should ideally be tailored to the needs of the individual patient, with consideration of the medical needs of the child and the quality of life of the patient and family [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. These choices are based on the child&rsquo;s age, body size, associated nonrenal diseases, nutritional status, and transport characteristics of the peritoneal membrane, as well as the social, educational and economic status of the family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170768844\">",
"    <span class=\"h2\">",
"     Choice of modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;For both children and adults, peritoneal dialysis (PD) modalities are divided into manual and automated options:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Continuous ambulatory peritoneal dialysis (CAPD)",
"     </li>",
"     <li>",
"      Automated peritoneal dialysis (APD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170768851\">",
"    <span class=\"h3\">",
"     Continuous ambulatory PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous ambulatory peritoneal dialysis (CAPD) provides continuous solute and fluid removal throughout the day and night. In this manual form of chronic peritoneal dialysis (CPD), the patient or caregiver attaches and instills a bag of sterile dialysis fluid into the peritoneal cavity four times per day through a surgically placed catheter, followed by drainage through the same catheter after a predetermined period of time (referred to as the dwell time). The filling and draining of fluid constitutes an exchange. Each of the three daytime exchanges last approximately five hours, and the nighttime exchange nine hours. The advantages of CAPD are its ease of use and the limited cost of equipment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170768858\">",
"    <span class=\"h3\">",
"     Automated PD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Automated peritoneal dialysis (APD) is broadly defined as all forms of PD that employ the use of a cycler [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. If it is available and there are no financial constraints, APD is the preferred modality for pediatric patients because it allows for a wide range of treatment options, which is more easily tailored than CAPD to the individual needs of the child.",
"   </p>",
"   <p>",
"    In general, multiple automated exchanges are performed at night while the patient is sleeping. The supine position is superior to the upright position for solute and fluid transport because there is better tolerance of large fill volumes, which increases the contact area of the peritoneal membrane and dialysate.",
"   </p>",
"   <p>",
"    There are currently three APD options that include multiple nocturnal exchanges:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nightly intermittent PD (NIPD) &ndash; In NIPD, there are a number of short automated nocturnal exchanges, but no dialysis exchange during the day. Thus, solute and fluid removal only take place at night.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Advantages of a dry peritoneal cavity during the day include normal intraperitoneal pressure (IPP) and a decreased risk for hernia formation, reduction of glucose absorption from dialysate, reduction of amino acid and protein loss, and reduction of peritoneal membrane exposure to glucose. (See",
"      <a class=\"local\" href=\"#H15616800\">",
"       'Increased intraperitoneal pressure related complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The absence of a daytime dwell limits solute clearance; thus, NIPD is generally not a suitable choice in patients with little or no residual renal function (RRF).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Continuous cycling peritoneal dialysis (CCPD) &ndash; In CCPD, automated nocturnal exchanges are followed by a prolonged daytime exchange (dialysis solution volume of 50 to 100 percent of the nocturnal volume), applied at the conclusion of the nocturnal APD session and left in the abdomen until the start of the next nocturnal dialysis session.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      CCPD provides continuous solute and fluid removal throughout the day and night.",
"     </li>",
"     <li>",
"      CCPD is recommended when RRF becomes negligible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tidal peritoneal dialysis (TPD) &ndash; In TPD, an initial infusion of dialysis solution into the peritoneal cavity is followed by only partial drainage of the peritoneal volume during each exchange. As a result, an intra-abdominal volume of dialysate is retained at the end of each exchange, so there is constant contact between dialysis solution and the peritoneal membrane.",
"      <br/>",
"      <br/>",
"      Partial drain volume is replaced by fresh dialysate to restore the initial intra-infusion volume with each cycle. The entire dialysate volume is drained at the end of the session.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      TPD provides continuous solute and fluid removal throughout the day and night.",
"     </li>",
"     <li>",
"      It is commonly used for patients with mechanical (eg, drainage of dialysate) problems and as a means of alleviating discomfort in patients experiencing drainage pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H15616785\">",
"       'Non-infectious complications'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The tidal drain volume can be adapted to the drainage profile of the patient to increase dialysis efficiency. The rate of outflow is not linear and is highest at the beginning of the drain time and then significantly drops to a breakpoint when a critical intraperitoneal volume is reached. Elimination of the time at this breakpoint necessary for complete drainage decreases the time period when solute clearance is greatly reduced.",
"     </li>",
"     <li>",
"      TPD requires more dialysate solution and is technically more difficult to perform than CCPD or NIPD.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    APD is performed through a specific pediatric mode of the cycler. In small children and infants, this allows for more accurate delivery of small dialysate volumes. As a result of technological advancements, software computer programs can record compliance to the dialysis prescription, delivered dialysis volume, the amount of fluid removed (eg, ultrafiltrate), and the drainage profile of each exchange. This information can be downloaded from the memory card of the cycler or be retrieved via a modem on a regular basis and is used to improve and update the PD prescription.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170770118\">",
"    <span class=\"h2\">",
"     PD catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful CPD is dependent on the placement of a reliable access. A two-cuffed Tenckhoff catheter is preferred because use of double cuff versus single cuff catheters is associated with a lower incidence of peritonitis and access revisions, and a longer time to first peritonitis episode [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=see_link&amp;anchor=H2#H2\">",
"     \"Placement and maintenance of the peritoneal dialysis catheter\", section on 'Types of catheters'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catheters should be surgically placed in a paramedian or lateral abdominal location. The deep cuff is placed in or below the rectus muscle, and the superficial cuff is located approximately 2 cm below the skin surface. The catheter should be placed with a downward-pointed exit site position to reduce the risk of peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/11\">",
"     11",
"    </a>",
"    ]. Other considerations include placement of the exit site away from a (or potential) gastrostomy site, and outside the diaper area in infants and small children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616710\">",
"    <span class=\"h2\">",
"     Peritoneal membrane function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transport capacity of a patient&rsquo;s peritoneal membrane is one of the most important characteristics to consider when determining the dialysis prescription. The most widely used test is the peritoneal equilibration test (PET), which assesses the overall solute transport rates across the peritoneum. It categorizes patients based on their solute transport rates and serves as the basis for the patient&rsquo;s dialysis prescription. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, this standardized test measures small solute transfer across the peritoneal membrane and net ultrafiltration during a four hour dwell using an exchange volume of 1100",
"    <span class=\"nowrap\">",
"     mL/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    BSA (body surface area) of a 2.5 percent dextrose-containing dialysate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/12\">",
"     12",
"    </a>",
"    ]. It is important to recognize that the test exchange volume significantly impacts the PET results (eg, small volume associated with high solute transport capacity). Several studies have validated this test volume for the PET and have shown consistent results that are similar to the results in adults using the standard test exchange volume of 2 L [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Using the BSA adjusted test volume, there appears to be no difference in the peritoneal membrane transport capacity and function between children and adults.",
"   </p>",
"   <p>",
"    Infants and young children (below two years of age), however, may not tolerate a test volume of 1100",
"    <span class=\"nowrap\">",
"     mL/",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    . In these patients, the test volume generally used is the clinically prescribed fill volume. (See",
"    <a class=\"local\" href=\"#H170769281\">",
"     'Fill volume'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    PET is used clinically as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiation of dialysis to determine the dialysis prescription &ndash; A PET evaluation is conducted four to eight weeks following the initiation of PD, with subsequent evaluation and possible modification of the initial PD prescription.",
"     </li>",
"     <li>",
"      Monitor membrane function &ndash; Because of changes in the peritoneal membrane function that may occur, the PET is used to monitor membrane function and help guide changes in the dialysis prescription. PET should be repeated when there is concern for membrane injury or changes (eg, repeated episodes of peritonitis)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      clinical evidence of altered transport characteristics (eg, fluid retention with increased blood pressure or worsening symptoms of uremia).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical applications of the PET are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link&amp;anchor=H4#H4\">",
"     \"Peritoneal equilibration test\", section on 'Clinical applications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616717\">",
"    <span class=\"h2\">",
"     Prescription components",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are the elements of the peritoneal prescription after selecting the CPD modality:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Selection of PD solutions",
"     </li>",
"     <li>",
"      Determination of the fill volume",
"     </li>",
"     <li>",
"      Determination of dwell time and number of exchanges",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prescription is based on the individual patient needs for solute transfer and removal of fluid, both of which can be increased by changes in the prescription, such as increasing the osmolality of the solution, fill volume,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    number of exchanges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170769273\">",
"    <span class=\"h3\">",
"     Solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several different solutions are available commercially for peritoneal dialysis and all include the following components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Water",
"     </li>",
"     <li>",
"      Buffers to control acidosis (eg, acetate, lactate, or bicarbonate)",
"     </li>",
"     <li>",
"      Electrolytes (ie, sodium, calcium, chloride, and magnesium)",
"     </li>",
"     <li>",
"      Osmotic agent; usually dextrose in varying concentrations (1.5, 2.5, and 4.25 percent solutions). Increasing the osmolality will increase net fluid removal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these solutions satisfactorily remove fluid and transfer solutes, and generally maintain adequate electrolyte, acid-base, and mineral homeostasis, there is increasing evidence that prolonged exposure to standard PD solutions results in membrane injury and reduced function, especially in patients who are exposed to the frequent and short cycles used in APD [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. In particular, solutions with high concentrations of glucose and lactate appear to be more injurious.",
"   </p>",
"   <p>",
"    Therefore, development of more biocompatible solutions is desirable, especially for pediatric patients in whom preserving a functional membrane is important so that CPD can be maintained as a long-term dialysis modality. Amino acids and bicarbonate have been used to improve biocompatibility. In addition, higher molecular weight glucose polymers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     icodextrin",
"    </a>",
"    , increase ultrafiltration so the number of exchanges may be reduced. However, data are limited in children, and further studies are warranted to see if these strategies improve long-term peritoneal membrane function without significant adverse effects [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In addition, there is limited availability of many of these biocompatible solutions in different parts of the world. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=see_link\">",
"     \"Peritoneal dialysis solutions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H170769281\">",
"    <span class=\"h3\">",
"     Fill volume",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prescribed fill volume is based on the BSA of the child. It is adjusted based on the patient&rsquo;s tolerance and need for solute and fluid removal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a CAPD regimen of four exchanges per day, a fill volume of 900 to 1100",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      BSA (35 to 45",
"      <span class=\"nowrap\">",
"       mL/kg)",
"      </span>",
"      of 2.5 percent dextrose dialysis solution generally yields net fluid removal (ultrafiltration [UF]) volumes of up to 1100",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      with acceptable biochemical control. In other cases, dialysis solutions of 1.5 percent dextrose may provide acceptable ultrafiltration.",
"     </li>",
"     <li>",
"      In patients managed by APD, targeted individual nocturnal fill volume is 1000 to 1200",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for patients &gt;2 years, and 600 to 800",
"      <span class=\"nowrap\">",
"       mL/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      for children &le; 2 years of age. The daytime fill volume is generally 50 percent of the nighttime volume. The UF using this modality is dependent on cycle frequency, fill volume, osmolality of the dialysis solution, and the transport capacity of the child&rsquo;s peritoneal membrane. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Too small a fill volume may lead to rapid solute equilibration and inadequate ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, too large a volume can lead to excessive increases in intraperitoneal pressure (IPP) that reduces dialysis efficiency due to enhanced lymphatic uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/18\">",
"     18",
"    </a>",
"    ]. In addition, large fill volumes may not be well tolerated by the child due to",
"    <span class=\"nowrap\">",
"     discomfort/pain,",
"    </span>",
"    dyspnea, hernia, gastroesophageal reflux, and hydrothorax. In these cases, the IPP measurement may be useful in assessing patient tolerance. In general, an IPP greater than 18 cm H",
"    <sub>",
"     2",
"    </sub>",
"    0 is associated with abdominal pain and a decrease in vital capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H15616785\">",
"     'Non-infectious complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616725\">",
"    <span class=\"h3\">",
"     Exchange dwell time",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of the dwell times is dependent on the CPD modality selected.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In CAPD, the dwell times are long, and therefore, the major risk to dialysis efficiency is loss of the glucose-related osmotic gradient due to solute equilibration that results in ineffective ultrafiltration and dialysate reabsorption by the child. Thus, the dwell time may need to be shortened (less than four hours) in children who have high solute transport rates across the peritoneum based on peritoneal equilibration testing. (See",
"      <a class=\"local\" href=\"#H15616710\">",
"       'Peritoneal membrane function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In APD, an exchange dwell time of about one hour is initially selected. However, the dwell time needs to be reevaluated and possibly modified based on the needs of the individual patient, taking into consideration the patient&rsquo;s RRF, peritoneal membrane transport function, and the desired clinical goals. Dwell times are shortened to increase ultrafiltration and urea clearance. Long dwell time exchanges, on the other hand, favor higher creatinine and phosphate clearance but may impair ultrafiltration. Commercially available modeling programs designed to assist in the prescription process have been validated in children [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263453046\">",
"    <span class=\"h1\">",
"     INFECTIOUS COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616740\">",
"    <span class=\"h2\">",
"     Peritonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritonitis remains the most significant complication of chronic peritoneal dialysis (CPD) in the pediatric population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Peritonitis contributes to significant morbidity because of loss of peritoneal membrane function and technique failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the 2011 annual report, the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) reported on 4248 episodes of peritonitis in 6658&nbsp;years of follow-up for an annualized rate of 0.64 (one episode every 18.8&nbsp;months) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/11\">",
"     11",
"    </a>",
"    ]. As seen in earlier reports, the data also revealed an inverse relationship between the age of the patient and peritonitis rate, with the youngest patients (&lt;1&nbsp;year) having an annualized rate of 0.79 (one infection every 15.3&nbsp;months), while the adolescents (&gt;12&nbsp;years) have a rate of 0.57 (one infection every 21.2&nbsp;months).",
"   </p>",
"   <p>",
"    Although, the microbiology, diagnosis, and management of peritonitis in children undergoing CPD are similar to that of adult patients, there are some issues that are unique or more common in pediatric CPD. This includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fungal peritonitis is an infrequent complication in pediatric patients undergoing CPD accounting for less than 5 percent of peritonitis episodes. Successful therapy is the same as in adults with fungal peritonitis and consists of combination therapy of antifungal medication and dialysis catheter removal. The outcome of fungal peritonitis in children, however, is more favorable than in adults with a lower mortality rate [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/24\">",
"       24",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=see_link\">",
"       \"Fungal peritonitis in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is global variation in causative microbial agent in peritonitis in children receiving CPD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/25\">",
"       25",
"      </a>",
"      ]. As an example, the rate of Pseudomonas-based peritonitis is eight times greater in the United States than in Europe. In addition, there are significant differences in antibiotic susceptibility, particularly with first generation cephalosporins and aminoglycosides. These issues need to be considered when choosing empiric antibiotic coverage while awaiting results from peritoneal fluid cultures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predisposing factors in children that may contribute to peritonitis include the higher incidence of gastrostomy feeds and the use of diapers in infants and young children who are not yet toilet trained.",
"   </p>",
"   <p>",
"    The microbiology, presentation, diagnosis, and management of peritonitis in patients undergoing CPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=see_link\">",
"     \"Microbiology and therapy of peritonitis in continuous peritoneal dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=see_link\">",
"     \"Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616778\">",
"    <span class=\"h2\">",
"     Exit-site and tunnel infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis catheter",
"    <span class=\"nowrap\">",
"     exit-site/tunnel",
"    </span>",
"    infections are a significant cause of peritonitis and catheter failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a review of the NAPRTCS data from 1992 to 1997, the incidence of",
"      <span class=\"nowrap\">",
"       exit-site/tunnel",
"      </span>",
"      infections was 30 percent by one year after catheter insertion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 82 catheter related infections (exit-site and tunnel infections) occurring in 93 children treated with peritoneal dialysis (PD) at a single center during 2670 patient months of dialysis, Staphylococcus aureus and Pseudomonas aeruginosa were the two most common causative organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment of catheter exit-site infections routinely consists of oral antibiotics according to",
"    <span class=\"nowrap\">",
"     culture/susceptibility",
"    </span>",
"    results. Intraperitoneal antibiotics are added only if improvement is not seen promptly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263453219\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of exit-site infections (ESIs) is the primary goal of exit-site care, which consists of aseptic care, daily assessment and cleansing of the exit-site, immobilization of the catheter, and protection of the exit-site and subcutaneous catheter tunnel from trauma. Proper handwashing technique is of utmost importance and should be practiced by the individual conducting exit-site care [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/28\">",
"     28",
"    </a>",
"    ]. Cleansing should be performed with a non-cytotoxic and non-alcoholic antiseptic agent, such as sodium hypochlorite or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/9/44180?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    , as opposed to soap and water. In addition, many centers use topical antibiotic prophylaxis to prevent bacterial infection. As an example, topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    has been used to decrease S. Aureus colonization because of the recognized risk of S. Aureus peritonitis in patients with S. Aureus nasal carriage.",
"   </p>",
"   <p>",
"    The effect of preventive measures to reduce exit-site infections and peritonitis was shown in a retrospective review from a single center that reported a reduction in catheter-related infections and prolonged catheter survival with the introduction of daily cleansing with sodium hypochlorite and application of topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/18/43300?source=see_link\">",
"     mupirocin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/29\">",
"     29",
"    </a>",
"    ]. However, the association between mupirocin usage and pseudomonas infections has prompted the use of topical",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"     gentamicin",
"    </a>",
"    cream in some centers, as it covers potential Gram-positive and the Gram-negative pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=see_link&amp;anchor=H2#H2\">",
"     \"Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis\", section on 'Prevention of catheter infections'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616785\">",
"    <span class=\"h1\">",
"     NON-INFECTIOUS COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal dialysis (PD) non-infectious complications can be divided into mechanical, technique-related, and catheter-related complications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616792\">",
"    <span class=\"h2\">",
"     Mechanical complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616800\">",
"    <span class=\"h3\">",
"     Increased intraperitoneal pressure related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of chronic peritoneal dialysis (CPD) related to increased intraabdominal pressure include",
"    <strong>",
"    </strong>",
"    hernias, fluid leaks, and hydrothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hernias are commonly incisional, umbilical, or inguinal, occurring with a reported frequency of 11.8 to 53 percent in children undergoing CPD [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/33-35\">",
"       33-35",
"      </a>",
"      ]. The incidence is inversely proportional to age, with the highest frequency occurring within the first year of life [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/33\">",
"       33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=see_link\">",
"       \"Abdominal hernias in continuous peritoneal dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fluid leaks may occur early (defined as occurring less than 30 days after catheter insertion) or late. Early leaks often occur at the PD catheter exit-site, while late leaks more commonly occur into the abdominal wall, leading to abdominal wall or genital edema, and are more likely to be associated with hernias. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link&amp;anchor=H14#H14\">",
"       \"Noninfectious complications of peritoneal dialysis catheters\", section on 'Pericatheter leakage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hydrothorax, which may present as an incidental finding on chest x-ray, respiratory distress without volume overload, or with ultrafiltration failure, is an uncommon but potentially serious complication of CPD. It may result in PD technique failure and the need for transfer to hemodialysis if recurrent. Successful continuation of PD has been reported using reduced exchange volumes or following surgical correction of an identified pleuroperitoneal connection; resolution of the hydrothorax may also occasionally occur with temporary cessation of PD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22904?source=see_link&amp;anchor=H9#H9\">",
"       \"Noninfectious complications of continuous peritoneal dialysis\", section on 'Pleural effusion due to pleuroperitoneal leak'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616822\">",
"    <span class=\"h2\">",
"     Technique related complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616830\">",
"    <span class=\"h3\">",
"     Ultrafiltration failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrafiltration (UF) failure can lead to symptomatic volume overload and PD technique failure, especially in patients who are anephric or oliguric. Decreased ultrafiltration can occur as a result of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High peritoneal membrane solute transport capacity, with rapid dissipation of the glucose based osmotic gradient for UF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      May occur with long-term PD due to prolonged exposure to glucose degradation products (GDPs) present in conventional PD solutions [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      May occur as a result of peritonitis.",
"     </li>",
"     <li>",
"      May also be iatrogenic due to the use of a small fill volume relative to the peritoneal surface area.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased peritoneal lymphatic absorption secondary to elevated intraperitoneal pressure.",
"     </li>",
"     <li>",
"      Rarely, aquaporin (ultra small pore water channels in the peritoneum) deficiency. (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=see_link&amp;anchor=H4#H4\">",
"       \"Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis\", section on 'Aquaporin-1 and water transport'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sclerosing encapsulating peritonitis results in progressive decrease in UF. (See",
"      <a class=\"local\" href=\"#H350251105\">",
"       'Encapsulating peritoneal sclerosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616844\">",
"    <span class=\"h2\">",
"     Catheter related complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catheter related complications can occur in the immediate postoperative period or later, and include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leakage of dialysate around the catheter &ndash; Delaying catheter usage for one to two weeks following catheter placement or initial use of a small fill volume can decrease risk of leakage [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link&amp;anchor=H14#H14\">",
"       \"Noninfectious complications of peritoneal dialysis catheters\", section on 'Pericatheter leakage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catheter migration &ndash; Occurs less commonly with a PD catheter with a curled intraperitoneal segment, swan neck catheter, or a downward facing exit-site [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/39-41\">",
"       39-41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Extrusion of catheter cuff at exit-site with subsequent increased risk for infection, which can be prevented by placement of external cuff approximately 2 cm from the exit-site [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link&amp;anchor=H19#H19\">",
"       \"Noninfectious complications of peritoneal dialysis catheters\", section on 'Catheter cuff extrusion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Catheter outflow occlusion, usually caused by omentum, or adhesions to mesentery or other intra-abdominal structures. Partial omentectomy is often performed at time of catheter placement in an attempt to prevent catheter outflow occlusion [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/41,44,45\">",
"       41,44,45",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link&amp;anchor=H2#H2\">",
"       \"Noninfectious complications of peritoneal dialysis catheters\", section on 'Outflow failure'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350250243\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350250268\">",
"    <span class=\"h3\">",
"     Hemoperitoneum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of hemoperitoneum as a complication of PD in children is reported to be 1.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/46\">",
"     46",
"    </a>",
"    ]. Conventional treatment of hemoperitoneum includes the addition of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    to the dialysis fluid to prevent catheter occlusion from clots; however, management depends on the severity and underlying cause. The etiology, evaluation, and management of hemoperitoneum in patients undergoing CPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=see_link\">",
"     \"Bloody peritoneal dialysate (hemoperitoneum)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350250381\">",
"    <span class=\"h3\">",
"     Pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal pain can be observed, even in the absence of peritonitis. Typically, pain is referred to the shoulder and is associated with infusion of dialysis fluid or at the end of draining. Causes of abdominal pain include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Jet of dialysis fluid or catheter irritation in the dry peritoneal cavity. The use of a PD catheter with a curled intraperitoneal segment has been associated with a decreased incidence of jet-related pain.",
"     </li>",
"     <li>",
"      Overdistention of the peritoneal cavity with excessive dialysis fluid due to cycler malfunction, catheter malfunction, and incomplete drainage prior to subsequent filling.",
"     </li>",
"     <li>",
"      Intra-abdominal processes unrelated to the dialysis procedure such as peptic ulcer disease, pancreatitis, or diffuse peritoneal calcification. In a case report, tidal peritoneal dialysis effectively provided symptomatic relief of pain in a child with peritoneal calcifications [",
"      <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other causes of pain during dialysate infusion include acidic dialysate fluid, malposition of the catheter, and high glucose concentration of hypertonic dialysis solutions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22904?source=see_link&amp;anchor=H16#H16\">",
"     \"Noninfectious complications of continuous peritoneal dialysis\", section on 'Pain on dialysate infusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350251105\">",
"    <span class=\"h3\">",
"     Encapsulating peritoneal sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encapsulating peritoneal sclerosis (EPS) is a rare, potentially devastating complication of PD, which leads to progressive loss of UF and can result in abdominal pain, ascites, intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/48\">",
"     48",
"    </a>",
"    ], and death. Risk factors implicated in the development of SEP include prolonged duration of peritoneal dialysis, recurrent bacterial peritonitis, and prolonged exposure to hypertonic dialysis solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/49-55\">",
"     49-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H797529\">",
"    <span class=\"h3\">",
"     Nutritional and metabolic issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nutritional and metabolic issues associated with CPD include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Protein loss (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14519?source=see_link&amp;anchor=H3#H3\">",
"       \"Nutritional status and protein intake in continuous peritoneal dialysis\", section on 'Protein intake'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hyponatremia due to sodium loss",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616851\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15616859\">",
"    <span class=\"h2\">",
"     Patient survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient mortality rates in children receiving chronic peritoneal dialysis (CPD) are significantly greater than the rates in transplanted children or the healthy population. Based on the USRDS 2009 Annual Data Report, patient three year survival probability was reported to be lowest in the 0 to 4 year age group at 83 percent as compared with 96, 93, and 95 percent in the 5 to 9 year, 10 to 14 year, and 15 to 19 year age groups, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/56\">",
"     56",
"    </a>",
"    ]. Data from the Italian dialysis registry has also documented the highest mortality rates in the youngest patients (&lt;5 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common causes of death for pediatric PD patients of all ages are cardiovascular disease and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Pulmonary disease and severe",
"    <span class=\"nowrap\">",
"     oliguria/anuria",
"    </span>",
"    appear to be significant risk factors for mortality in infants and young children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263453462\">",
"    <span class=\"h2\">",
"     Transition to hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need to terminate CPD for reasons other than transplantation is most commonly the result of infectious complications. A NAPRTCS study found that 20 percent of patients transitioned from PD to hemodialysis (HD) over a six-year period, most commonly (43 percent) due to infection, followed by ultrafiltration failure,",
"    <span class=\"nowrap\">",
"     patient/family",
"    </span>",
"    choice, and access failure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/31/28153/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263453553\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic peritoneal dialysis (CPD) is the most common dialysis treatment modality used to treat pediatric patients with end-stage renal disease (ESRD), particularly in children less than five years of age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no comparative studies of peritoneal dialysis (PD) and hemodialysis (HD) outcomes in children with ESRD to suggest superiority of one procedure versus the other. Advantages associated with CPD include a less restricted diet, dialysis treatment can be performed at home, and no need for vascular access and repeated venipuncture. Disadvantages of CPD include increased caregiver burden and risks of potential nonadherence, and CPD related infections. Contraindications to CPD include specific conditions that affect the integrity of the abdominal cavity and peritoneum. (See",
"      <a class=\"local\" href=\"#H3926445\">",
"       'Peritoneal dialysis versus hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selection of the PD modality and the specific prescription should ideally be tailored to the needs of the individual patient, with consideration of the medical needs of the child and the quality of life of the patient and family. These choices are based on the child&rsquo;s age, body size, associated nonrenal diseases, nutritional status, and transport characteristics of the peritoneal membrane, as well as the social, educational, and economic status of the family. (See",
"      <a class=\"local\" href=\"#H15616702\">",
"       'Prescribing peritoneal dialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      PD modalities are divided into manual and automated options.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Continuous ambulatory PD (CAPD) is the manual form of CPD that provides continuous solute and fluid removal throughout the day and night. It is easier to use and less costly than the automated PD options. (See",
"      <a class=\"local\" href=\"#H170768851\">",
"       'Continuous ambulatory PD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Automated PD (APD) uses a cycler that performs multiple exchanges at night. It allows for a wide range of treatment options, which can be more easily tailored to the patient&rsquo;s needs than CAPD. The three options of APD are nightly intermittent PD, continuous cycling PD, and tidal peritoneal dialysis. (See",
"      <a class=\"local\" href=\"#H170768858\">",
"       'Automated PD'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Successful CPD is dependent on the placement of a reliable access. In the pediatric patient, we suggest using a two-cuffed Tenckhoff catheter rather than a single-cuffed catheter to reduce the risk of peritonitis (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Placement of the catheter with a downward-pointed exit site position also reduces the risk of peritonitis. (See",
"      <a class=\"local\" href=\"#H170770118\">",
"       'PD catheter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that a peritoneal equilibration test (PET) be performed in all children undergoing CPD to determine the solute transfer characteristics of the peritoneal membrane, which can assist in developing an adequate dialysis prescription (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Test exchange volume is determined by the body surface area of the child. (See",
"      <a class=\"local\" href=\"#H15616710\">",
"       'Peritoneal membrane function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The elements of the peritoneal prescription include selection of PD solutions and determination of the fill volume, dwell time, and the number of exchanges. The prescription is based on the individual patient needs for solute transfer and removal of fluid, both of which can be increased by changes in the prescription, such as increasing the osmolality of the solution, fill volume,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      number of exchanges. (See",
"      <a class=\"local\" href=\"#H15616717\">",
"       'Prescription components'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infectious complications of CPD include peritonitis, and catheter",
"      <span class=\"nowrap\">",
"       exit-site/tunnel",
"      </span>",
"      infections. We recommend daily care of the exit-site and catheter that reduces the risk of exit-site and tunnel infections (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). This includes proper handwashing of the care provider, daily assessment and cleansing of the exit-site with antiseptic agents, catheter immobilization, trauma avoidance to the exit-site and subcutaneous catheter, and the use of topical antibiotic prophylaxis. (See",
"      <a class=\"local\" href=\"#H263453046\">",
"       'Infectious complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Noninfectious complications are divided into the following categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Mechanical complications due to increased intraperitoneal pressure include hernia, fluid leak, and hydrothorax. (See",
"      <a class=\"local\" href=\"#H15616792\">",
"       'Mechanical complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Technique-related complications include ultrafiltration failure, which may be due to rapid solute transfer, increased lymphatic flow, or aquaporin deficiency. (See",
"      <a class=\"local\" href=\"#H15616822\">",
"       'Technique related complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Catheter-related complications include dialysate leakage, catheter migration, cuff extrusion, and outflow occlusion. (See",
"      <a class=\"local\" href=\"#H15616844\">",
"       'Catheter related complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other complications include hemoperitoneum, pain, sclerosing encapsulating peritonitis, and nutritional and metabolic problems. (See",
"      <a class=\"local\" href=\"#H350250243\">",
"       'Other complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient mortality rates in children receiving CPD are significantly greater than the rates in transplanted children or the healthy population. The most common causes of death for pediatric CPD patients of all ages are cardiovascular disease and infection. Pulmonary disease and severe",
"      <span class=\"nowrap\">",
"       oliguria/anuria",
"      </span>",
"      appear to be significant risk factors for mortality in infants and young children. (See",
"      <a class=\"local\" href=\"#H15616859\">",
"       'Patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The need to terminate CPD and transition to HD is most commonly the result of infectious complications. (See",
"      <a class=\"local\" href=\"#H263453462\">",
"       'Transition to hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/1\">",
"      Hattori S, Yosioka K, Honda M, et al. The 1998 report of the Japanese National Registry data on pediatric end-stage renal disease patients. Pediatr Nephrol 2002; 17:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/2\">",
"      Verrina E, Edefonti A, Gianoglio B, et al. A multicenter experience on patient and technique survival in children on chronic dialysis. Pediatr Nephrol 2004; 19:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/3\">",
"      Fadrowski JJ, Frankenfield D, Amaral S, et al. Children on long-term dialysis in the United States: findings from the 2005 ESRD clinical performance measures project. Am J Kidney Dis 2007; 50:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/4\">",
"      Warady BA, Alexander SR, Watkins S, et al. Optimal care of the pediatric end-stage renal disease patient on dialysis. Am J Kidney Dis 1999; 33:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/5\">",
"      Verrina E, Cappelli V, Perfumo F. Selection of modalities, prescription, and technical issues in children on peritoneal dialysis. Pediatr Nephrol 2009; 24:1453.",
"     </a>",
"    </li>",
"    <li>",
"     Verrina E. Peritoneal Dialysis. In: Pediatric Nephrology, Avner ED HW, Niaudet P, Yoshikawa N (Eds), Springer-Verlag, Berlin Heidelberg 2009. p.1785.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/7\">",
"      Tsai TC, Liu SI, Tsai JD, Chou LH. Psychosocial effects on caregivers for children on chronic peritoneal dialysis. Kidney Int 2006; 70:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/8\">",
"      Centers for Medicare and Medicaid Services, Kinney R. 2005 Annual Report: ESRD Clinical Performance Measures Project. Am J Kidney Dis 2006; 48:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/9\">",
"      Fischbach M, Warady BA. Peritoneal dialysis prescription in children: bedside principles for optimal practice. Pediatr Nephrol 2009; 24:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/10\">",
"      H&ouml;ltt&auml; T, R&ouml;nnholm K, Holmberg C. Adequacy of dialysis with tidal and continuous cycling peritoneal dialysis in children. Nephrol Dial Transplant 2000; 15:1438.",
"     </a>",
"    </li>",
"    <li>",
"     North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2011 Annual Report: renal transplantation, dialysis, chronic renal insufficiency. file://www.emmes.com/study/ped/annlrept/annualrept2011.pdf (Accessed on June 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/12\">",
"      Warady BA, Alexander SR, Hossli S, et al. Peritoneal membrane transport function in children receiving long-term dialysis. J Am Soc Nephrol 1996; 7:2385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/13\">",
"      Warady BA, Alexander S, Hossli S, et al. The relationship between intraperitoneal volume and solute transport in pediatric patients. Pediatric Peritoneal Dialysis Study Consortium. J Am Soc Nephrol 1995; 5:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/14\">",
"      de Boer AW, van Schaijk TC, Willems HL, et al. The necessity of adjusting dialysate volume to body surface area in pediatric peritoneal equilibration tests. Perit Dial Int 1997; 17:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/15\">",
"      Bouts AH, Davin JC, Groothoff JW, et al. Standard peritoneal permeability analysis in children. J Am Soc Nephrol 2000; 11:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/16\">",
"      Schr&ouml;der CH. New peritoneal dialysis fluids: practical use for children. Pediatr Nephrol 2003; 18:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/17\">",
"      Canepa A, Verrina E, Perfumo F. Use of new peritoneal dialysis solutions in children. Kidney Int Suppl 2008; :S137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/18\">",
"      Fischbach M, Terzic J, Menouer S, et al. Impact of fill volume changes on peritoneal dialysis tolerance and effectiveness in children. Adv Perit Dial 2000; 16:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/19\">",
"      Fischbach M, Dheu C, Seug&eacute;-Dargnies L, Delobbe JF. Adequacy of peritoneal dialysis in children: consider the membrane for optimal prescription. Perit Dial Int 2007; 27 Suppl 2:S167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/20\">",
"      Warady BA, Watkins SL, Fivush BA, et al. Validation of PD Adequest 2.0 for pediatric dialysis patients. Pediatr Nephrol 2001; 16:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/21\">",
"      Warady BA, Sullivan EK, Alexander SR. Lessons from the peritoneal dialysis patient database: a report of the North American Pediatric Renal Transplant Cooperative Study. Kidney Int Suppl 1996; 53:S68.",
"     </a>",
"    </li>",
"    <li>",
"     Tranaeus A. Peritonitis in pediatric continuous peritoneal dialysis. In: CAPD/CCPD in children, Fine RN AS, Warady BA (Eds), Kluwer, Morwell 1998. p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/23\">",
"      Warady BA, Feneberg R, Verrina E, et al. Peritonitis in children who receive long-term peritoneal dialysis: a prospective evaluation of therapeutic guidelines. J Am Soc Nephrol 2007; 18:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/24\">",
"      Warady BA, Bashir M, Donaldson LA. Fungal peritonitis in children receiving peritoneal dialysis: a report of the NAPRTCS. Kidney Int 2000; 58:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/25\">",
"      Schaefer F, Feneberg R, Aksu N, et al. Worldwide variation of dialysis-associated peritonitis in children. Kidney Int 2007; 72:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/26\">",
"      Furth SL, Donaldson LA, Sullivan EK, et al. Peritoneal dialysis catheter infections and peritonitis in children: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 2000; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/27\">",
"      Aksu N, Yavascan O, Anil M, et al. A ten-year single-centre experience in children on chronic peritoneal dialysis--significance of percutaneous placement of peritoneal dialysis catheters. Nephrol Dial Transplant 2007; 22:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/28\">",
"      Pittet D, Allegranzi B, Boyce J, World Health Organization World Alliance for Patient Safety First Global Patient Safety Challenge Core Group of Experts. The World Health Organization Guidelines on Hand Hygiene in Health Care and their consensus recommendations. Infect Control Hosp Epidemiol 2009; 30:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/29\">",
"      Chua AN, Goldstein SL, Bell D, Brewer ED. Topical mupirocin/sodium hypochlorite reduces peritonitis and exit-site infection rates in children. Clin J Am Soc Nephrol 2009; 4:1939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/30\">",
"      Bernardini J, Bender F, Florio T, et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16:539.",
"     </a>",
"    </li>",
"    <li>",
"     Harvey E. Non-infectious complications of peritoneal dialysis and hemodialysis. In: Pediatric Dialysis, BA Warady FS, RN Fine, SR Alexander (Eds), Kluwer Academic Publishers, Dordrecht 2004. p.415.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/32\">",
"      Bargman JM. Complications of peritoneal dialysis related to increased intraabdominal pressure. Kidney Int Suppl 1993; 40:S75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/33\">",
"      von Lilien T, Salusky IB, Yap HK, et al. Hernias: a frequent complication in children treated with continuous peritoneal dialysis. Am J Kidney Dis 1987; 10:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/34\">",
"      van Asseldonk JP, Schr&ouml;der CH, Severijnen RS, et al. Infectious and surgical complications of childhood continuous ambulatory peritoneal dialysis. Eur J Pediatr 1992; 151:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/35\">",
"      H&ouml;ltt&auml; TM, R&ouml;nnholm KA, Jalanko H, et al. Peritoneal dialysis in children under 5 years of age. Perit Dial Int 1997; 17:573.",
"     </a>",
"    </li>",
"    <li>",
"     Brandt M, Brewer E. Peritoneal dialysis access in children. In: Pediatric Dialysis, BA Warady FS, RN Fine, SR Alexander (Eds), Kluwer Academic Publishers, Dordrecht 2004. p.83.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/37\">",
"      Phan J, Stanford S, Zaritsky JJ, DeUgarte DA. Risk factors for morbidity and mortality in pediatric patients with peritoneal dialysis catheters. J Pediatr Surg 2013; 48:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/38\">",
"      Twardowski ZJ, Prowant BF. Exit-site healing post catheter implantation. Perit Dial Int 1996; 16 Suppl 3:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/39\">",
"      Twardowski ZJ, Prowant BF, Nichols WK, et al. Six-year experience with swan neck catheters. Perit Dial Int 1992; 12:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/40\">",
"      Hwang TL, Huang CC. Comparison of Swan neck catheter with Tenckhoff catheter for CAPD. Adv Perit Dial 1994; 10:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/41\">",
"      Harvey EA. Peritoneal access in children. Perit Dial Int 2001; 21 Suppl 3:S218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/42\">",
"      Flanigan M, Gokal R. Peritoneal catheters and exit-site practices toward optimum peritoneal access: a review of current developments. Perit Dial Int 2005; 25:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/43\">",
"      Campos RP, Chula DC, Riella MC. Complications of the peritoneal access and their management. Contrib Nephrol 2009; 163:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/44\">",
"      Conlin MJ, Tank ES. Minimizing surgical problems of peritoneal dialysis in children. J Urol 1995; 154:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/45\">",
"      Ladd AP, Breckler FD, Novotny NM. Impact of primary omentectomy on longevity of peritoneal dialysis catheters in children. Am J Surg 2011; 201:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/46\">",
"      Rinaldi S, Sera F, Verrina E, et al. The Italian Registry of Pediatric Chronic Peritoneal Dialysis: a ten-year experience with chronic peritoneal dialysis catheters. Perit Dial Int 1998; 18:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/47\">",
"      Warady BA, Bohl V, Alon U, Hellerstein S. Symptomatic peritoneal calcification in a child: treatment with tidal peritoneal dialysis. Perit Dial Int 1994; 14:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/48\">",
"      Tan FL, Loh D, Prabhakaran K. Sclerosing encapsulating peritonitis in a child secondary to peritoneal dialysis. J Pediatr Surg 2005; 40:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/49\">",
"      Araki Y, Hataya H, Tanaka Y, et al. Long-term peritoneal dialysis is a risk factor of sclerosing encapsulating peritonitis for children. Perit Dial Int 2000; 20:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/50\">",
"      Slingeneyer A, Mion C, Mourad G, et al. Progressive sclerosing peritonitis: a late and severe complication of maintenance peritoneal dialysis. Trans Am Soc Artif Intern Organs 1983; 29:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/51\">",
"      Dobbie JW. Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 1992; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/52\">",
"      Campbell S, Clarke P, Hawley C, et al. Sclerosing peritonitis: identification of diagnostic, clinical, and radiological features. Am J Kidney Dis 1994; 24:819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/53\">",
"      Nomoto Y, Kawaguchi Y, Kubo H, et al. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/54\">",
"      Mactier RA. The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis. Adv Perit Dial 2000; 16:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/55\">",
"      Nakayama M, Yamamoto H, Ikeda M, et al. Risk factors and preventive measures for encapsulating peritoneal sclerosis--Jikei experience 2002. Adv Perit Dial 2002; 18:144.",
"     </a>",
"    </li>",
"    <li>",
"     USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/57\">",
"      Rinaldi S, Sera F, Verrina E, et al. Chronic peritoneal dialysis catheters in children: a fifteen-year experience of the Italian Registry of Pediatric Chronic Peritoneal Dialysis. Perit Dial Int 2004; 24:481.",
"     </a>",
"    </li>",
"    <li>",
"     United States Renal Data System, USRDS 2009 Annual Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases., Bethesda, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/59\">",
"      Shroff R, Rees L, Trompeter R, et al. Long-term outcome of chronic dialysis in children. Pediatr Nephrol 2006; 21:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/60\">",
"      Rees L. Long-term peritoneal dialysis in infants. Perit Dial Int 2007; 27 Suppl 2:S180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/31/28153/abstract/61\">",
"      Shroff R, Ledermann S. Long-term outcome of chronic dialysis in children. Pediatr Nephrol 2009; 24:463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16400 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28153=[""].join("\n");
var outline_f27_31_28153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H263453553\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15616673\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3926445\">",
"      PERITONEAL DIALYSIS VERSUS HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616680\">",
"      Contraindications to CPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15616702\">",
"      PRESCRIBING PERITONEAL DIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170768844\">",
"      Choice of modality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170768851\">",
"      - Continuous ambulatory PD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170768858\">",
"      - Automated PD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H170770118\">",
"      PD catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616710\">",
"      Peritoneal membrane function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616717\">",
"      Prescription components",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170769273\">",
"      - Solutions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H170769281\">",
"      - Fill volume",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15616725\">",
"      - Exchange dwell time",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263453046\">",
"      INFECTIOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616740\">",
"      Peritonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616778\">",
"      Exit-site and tunnel infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H263453219\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15616785\">",
"      NON-INFECTIOUS COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616792\">",
"      Mechanical complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15616800\">",
"      - Increased intraperitoneal pressure related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616822\">",
"      Technique related complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15616830\">",
"      - Ultrafiltration failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616844\">",
"      Catheter related complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H350250243\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H350250268\">",
"      - Hemoperitoneum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H350250381\">",
"      - Pain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H350251105\">",
"      - Encapsulating peritoneal sclerosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H797529\">",
"      - Nutritional and metabolic issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15616851\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15616859\">",
"      Patient survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H263453462\">",
"      Transition to hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263453553\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41061?source=related_link\">",
"      Abdominal hernias in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24245?source=related_link\">",
"      Bloody peritoneal dialysate (hemoperitoneum)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/5/22617?source=related_link\">",
"      Clinical manifestations and diagnosis of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8631?source=related_link\">",
"      Fungal peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=related_link\">",
"      Hemodialysis for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33784?source=related_link\">",
"      Mechanisms of solute clearance and ultrafiltration in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17594?source=related_link\">",
"      Microbiology and therapy of peritonitis in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/23/22904?source=related_link\">",
"      Noninfectious complications of continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=related_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14519?source=related_link\">",
"      Nutritional status and protein intake in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=related_link\">",
"      Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18632?source=related_link\">",
"      Peritoneal dialysis solutions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/63/6136?source=related_link\">",
"      Placement and maintenance of the peritoneal dialysis catheter",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/60/3018?source=related_link\">",
"      Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_31_28154="Lichen planus flexures dark skin";
var content_f27_31_28154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F63590%7EDERM%2F76383%7EPC%2F50579%7EDERM%2F53839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F63590%7EDERM%2F76383%7EPC%2F50579%7EDERM%2F53839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous and hyperpigmented polygonal papules are present on ankles and ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous polygonal papules are present on the ventral wrists.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note discrete polygonal scaling erythematous papules on the wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus. Flat-topped, violaceous, polygonal papules on the flexor wrists are present. There are active and resolving lesions. Note the postinflammatory hyperpigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28154=[""].join("\n");
var outline_f27_31_28154=null;
var title_f27_31_28155="Radiographic views";
var content_f27_31_28155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Radiographic views for identifying fractures by location",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Anatomic region",
"      </td>",
"      <td class=\"subtitle1\">",
"       Plain radiograph fracture views",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wrist",
"      </td>",
"      <td>",
"       <p>",
"        All: AP, lateral",
"       </p>",
"       <p>",
"        Oblique: Fracture suspected but AP/lateral negative*",
"       </p>",
"       <p>",
"        Scaphoid: Scaphoid fracture suspected",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Elbow",
"      </td>",
"      <td>",
"       AP, lateral, oblique",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Shoulder",
"      </td>",
"      <td>",
"       AP, scapular Y",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Knee",
"      </td>",
"      <td>",
"       <p>",
"        AP, lateral, oblique&bull; (internal or externally rotated)",
"       </p>",
"       <p>",
"        Sunrise (axial, tangential): patellar injury",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Foot",
"      </td>",
"      <td>",
"       <p>",
"        AP, lateral",
"       </p>",
"       <p>",
"        Oblique: If fracture seen",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tibia, femur, humerus, and forearm",
"      </td>",
"      <td>",
"       AP, lateral",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ankle",
"      </td>",
"      <td>",
"       AP, lateral, and mortise&Delta;",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Allows view of the scaphoid-trapezoid-trapezium articulation.",
"     <br>",
"      &bull; Provides a different projection of the femoral condyles and tibial tuberosities as well as a cleaner view of the medial and lateral margins of the patella.",
"      <br>",
"       &Delta; The mortise view requires 10 to 20 degrees of internal rotation and allows the tibia and fibula to be viewed without superimposition on one another.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28155=[""].join("\n");
var outline_f27_31_28155=null;
var title_f27_31_28156="Hormone therapy for desmoids";
var content_f27_31_28156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F81891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F81891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hormone therapy in the treatment of desmoid tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agents used",
"       </td>",
"       <td class=\"subtitle1\">",
"        No of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of therapy (in months)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration of response",
"       </td>",
"       <td class=\"subtitle1\">",
"        Author, year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Toremifene or tamoxifen followed by toremifene*",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        1-29 (median 5.5)",
"       </td>",
"       <td>",
"        65 percent CBRR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Brooks M; 1992",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Testolactone",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        2-60 (median 6.5)",
"       </td>",
"       <td>",
"        <p>",
"         2 CR",
"         <sup>",
"          &bull;",
"         </sup>",
"        </p>",
"        <p>",
"         2 PR",
"        </p>",
"        <p>",
"         6 PD",
"        </p>",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Waddell W; 1991",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Progesterone",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        <p>",
"         6 CR",
"        </p>",
"        <p>",
"         2 PR",
"        </p>",
"        <p>",
"         3 SD/PD",
"         <sup>",
"          &Delta;",
"         </sup>",
"        </p>",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Lanari A; 1983",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Raloxifene",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        12-29",
"       </td>",
"       <td>",
"        <p>",
"         8 CR",
"        </p>",
"        <p>",
"         5 PR",
"        </p>",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Tonelli F; 2003",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Toremifene",
"       </td>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        <p>",
"         7 PR",
"        </p>",
"        <p>",
"         19 SD",
"        </p>",
"        <p>",
"         2 PD",
"        </p>",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        Fiore M; 2011",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CBRR: chemical benefit response rate; CR: complete response; PR: partial response; PD: progressive disease; NR: not reported; SD: stable disease.",
"     <br>",
"      * One patient was treated with toremifene for a month and discontinued due to blurry vision and was started on tamoxifen.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       In some cases response evaluation was accomplished by palpation.",
"       <br>",
"        &Delta; Author describes outcome as \"did not improve with progesterone\" and does not specify patients who had stable disease and progressive disease.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28156=[""].join("\n");
var outline_f27_31_28156=null;
var title_f27_31_28157="SSRI and SNRI meds";
var content_f27_31_28157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F81315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F81315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antidepressant medications: dosing and half-life information",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Generic drug name",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name (US)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual starting dose (mg)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Low starting dose (mg)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual daily dose (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Available oral doses (mg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mean half-life, hours (active metabolites)&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Selective serotonin reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citalopram",
"       </td>",
"       <td>",
"        Celexa",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        20 to 40",
"        <sup>",
"         &Delta;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        10, 20, 40, L",
"       </td>",
"       <td>",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escitalopram",
"       </td>",
"       <td>",
"        Lexapro",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        10 to 20",
"       </td>",
"       <td>",
"        5, 10, 20, L",
"       </td>",
"       <td>",
"        27 to 32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoxetine",
"       </td>",
"       <td>",
"        Prozac",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        20 to 60",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        10, 20, 40, L",
"       </td>",
"       <td>",
"        72 (216)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluoxetine Weekly",
"       </td>",
"       <td>",
"        Prozac Weekly",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        Luvox",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        50 to 300",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        25, 50, 100",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxetine",
"       </td>",
"       <td>",
"        Paxil",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        20 to 60&Delta;",
"       </td>",
"       <td>",
"        10, 20, 30, 40, L",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paroxetine CR",
"       </td>",
"       <td>",
"        Paxil CR",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        25 to 62.5",
"       </td>",
"       <td>",
"        12.5, 25, 37.5",
"       </td>",
"       <td>",
"        15 to 20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sertraline",
"       </td>",
"       <td>",
"        Zoloft",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        12.5 to 25",
"       </td>",
"       <td>",
"        50 to 200",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        25, 50, 100",
"       </td>",
"       <td>",
"        26 (66)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Serotonin-norepinephrine reuptake inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Duloxetine",
"       </td>",
"       <td>",
"        Cymbalta",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        60 to 90",
"       </td>",
"       <td>",
"        20, 30, 60",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine",
"       </td>",
"       <td>",
"        Effexor",
"       </td>",
"       <td>",
"        37.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        75 to 225",
"       </td>",
"       <td>",
"        25, 37.5, 50, 75, 100",
"       </td>",
"       <td>",
"        5 (11)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Venlafaxine XR",
"       </td>",
"       <td>",
"        Effexor XR",
"       </td>",
"       <td>",
"        37.5",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        75 to 225",
"       </td>",
"       <td>",
"        37.5, 75, 150",
"       </td>",
"       <td>",
"        5 (11)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     L: liquid; NA: not applicable; CR: controlled release; XR: extended release.",
"     <br>",
"      * Lower starting doses are recommended for elderly patients and patients with panic disorder, significant anxiety, or hepatic disease.",
"      <br>",
"       &bull; Mean half-lives of active metabolites are given in parentheses.",
"       <br>",
"        &Delta; Dose varies with diagnosis. Refer to text for specific guidelines.",
"        <br>",
"         &loz; Maximum recommended dose of citalopram is 20 mg for patients &gt;60 years of age, with significant hepatic insufficiency, or taking interacting medications that can increase citalopram levels. Refer to topics on unipolar depression for more information. Specific interactions of citalopram with other medications may be determined using the drug interactions tool (Lexi-Interact Online) included in UpToDate. This tool can be accessed from the UpToDate online search page or through the individual drug information topics in the section on Drug interactions.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Martinez M, Marangell LB, Martinez JM. Psychopharmacology. In: American Psychiatric Publishing Textbook of Psychiatry, 5th ed, Hales RE, Yudofsky SC, Gabbard, GO (Eds), American Psychiatric Publishing, Inc, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28157=[""].join("\n");
var outline_f27_31_28157=null;
var title_f27_31_28158="Cutaneous sporotrichosis";
var content_f27_31_28158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F74340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F74340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous sporotrichosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lesions on the back of a patient with cutaneous sporotrichosis who was thrown from his truck following a motor vehicle accident.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28158=[""].join("\n");
var outline_f27_31_28158=null;
var title_f27_31_28159="AGAI management GERD 1";
var content_f27_31_28159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51891%7EGAST%2F64967%7EGAST%2F76758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=21\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51891%7EGAST%2F64967%7EGAST%2F76758&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=21\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AGAI management GERD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the efficacy of lifestyle modifications for GERD? Which elements should be recommended and in which circumstances?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Weight loss should be advised for overweight or obese patients with esophageal GERD syndromes.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Elevation of the head of the bed for selected patients who are troubled with heartburn or regurgitation when recumbent. Other lifestyle modifications including, but not limited to, avoiding late meals, avoiding specific foods, or avoiding specific activities should be tailored to the circumstances of the individual patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Broadly advocating lifestyle changes for all (as opposed to selected) patients with GERD.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        How do antisecretory therapies compare in efficacy and under what circumstances might one be preferable to another? What is an acceptable upper limit of empirical therapy in patients with suspected typical esophageal GERD syndromes before performing esophagogastroduodenoscopy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Antisecretory drugs for the treatment of patients with esophageal GERD syndromes (healing esophagitis, and symptomatic relief). In these uses, proton pump inhibitors (PPIs) are more effective than histamine2 receptor antagonists (H2RAs), which are more effective than placebo.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Twice-daily PPI therapy for patients with an esophageal syndrome with an inadequate symptom response to once-daily PPI therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. A short course or as-needed use of antisecretory drugs in patients with a symptomatic esophageal syndrome without esophagitis when symptom control is the primary objective. For a short course of therapy, PPIs are more effective than H2RAs, which are more effective than placebo.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Metoclopramide as monotherapy or adjunctive therapy in patients with esophageal or suspected extraesophageal GERD syndromes.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kahrilas PJ, Shaheen NJ, Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008; 135:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AGAI management GERD (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the role and priority of diagnostic tests (endoscopy with or without biopsy, esophageal manometry, ambulatory pH monitoring, impedance-pH monitoring) in the evaluation of patients with suspected esophageal GERD syndromes?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Endoscopy with biopsy for patients with an esophageal GERD syndrome with troublesome dysphagia. Biopsies should target any areas of suspected metaplasia, dysplasia, or in the absence of visual abnormalities, normal mucosa (at least 5 samples to evaluate for eosinophilic esophagitis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Endoscopy to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of twice-daily PPI therapy. Biopsies should target any area of suspected metaplasia, dysplasia, or malignancy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        III. Manometry to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of twice-daily PPI therapy and have normal findings on endoscopy. Manometry will serve to localize the LES for potential subsequent pH monitoring, to evaluate peristaltic function preoperatively, and to diagnose subtle presentations of the major motor disorders. Evolving information suggests that high-resolution manometry has superior sensitivity to conventional manometry in recognizing atypical cases of achalasia and distal esophageal spasm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        IV. Ambulatory impedance-pH, catheter pH, or wireless pH monitoring (PPI therapy withheld for 7 days) to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of PPI therapy, have normal findings on endoscopy, and have no major abnormality on manometry. Wireless pH monitoring has superior sensitivity to catheter studies for detecting pathological esophageal acid exposure because of the extended period of recording (48 hours) and has also shown superior recording accuracy compared with some catheter designs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Using alarm symptoms (other than troublesome dysphagia) as a screening tool to identify patients with GERD at risk for esophageal adenocarcinoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Combined impedance-pH, catheter pH, or wireless pH monitoring studies to distinguish hypersensitivity syndromes from functional syndromes, the distinction being that in hypersensitivity syndromes symptoms are attributable to reflux events, whereas in functional syndromes they are not.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        III. Combined impedance-pH, catheter pH, or wireless pH esophageal monitoring studies performed while taking PPIs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are the unique management considerations in patients with suspected reflux chest pain syndrome?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Twice-daily PPI therapy as an empirical trial for patients with suspected reflux chest pain syndrome after a cardiac etiology has been carefully considered.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the best initial management for patients with suspected extraesophageal reflux syndromes (asthma, laryngitis, cough)? What are the unique management considerations with each? What is the appropriate dose and course of antisecretory therapy in each?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Acute or maintenance therapy with once- or twice-daily PPIs (or H2RAs) for patients with a suspected extraesophageal GERD syndrome (laryngitis, asthma) with a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Once- or twice-daily PPIs (or H2RAs) for acute treatment of patients with potential extraesophageal GERD syndromes (laryngitis, asthma) in the absence of a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Once- or twice-daily PPIs for patients with suspected reflux cough syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Does GERD progress in severity, such that symptomatic patients without esophagitis develop esophagitis and Barrett's metaplasia, or are these distinct disease manifestations that do not exist along a continuum? If patients do progress, at what rate does this occur, and does it warrant endoscopic monitoring?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Routine endoscopy in subjects with erosive or nonerosive reflux disease to assess for disease progression.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What maintenance therapy is indicated for patients with the typical esophageal reflux syndrome (with or without esophagitis)? When and how should antisecretory therapy be decreased or discontinued? What, if any, risks are associated with this?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Long-term use of PPIs for the treatment of patients with esophagitis once they have proven clinically effective. Long-term therapy should be titrated down to the lowest effective dose based on symptom control.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Less than daily dosing of PPI therapy as maintenance therapy in patients with an esophageal syndrome who previously had erosive esophagitis.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kahrilas PJ, Shaheen NJ, Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008; 135:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    AGAI management GERD (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What maintenance therapy is indicated for patients with suspected extraesophageal reflux syndromes (asthma, laryngitis, cough)? When and how should antisecretory therapy be decreased or discontinued?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Acute or maintenance therapy with once- or twice-daily PPIs (or H2RAs) for patients with a suspected extraesophageal GERD syndrome (laryngitis, asthma) with a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Maintenance therapy with once- or twice-daily PPIs (or H2RAs) for patients with potential extraesophageal GERD syndromes (laryngitis, asthma) in the absence of a concomitant esophageal GERD syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Once- or twice-daily PPIs for patients with suspected reflux cough syndrome.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are the clinical consequences of chronic potent acid inhibition? Do these potential side effects warrant specific testing (eg, bone density studies, calcium supplementation, Helicobacter pylori screening, and so on)?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Advocating bone density studies, calcium supplementation, Helicobacter pylori screening, or any other routine precaution because of PPI use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What is the role of endoscopy in long-term management of patients with GERD, and under what circumstances should mucosal biopsy specimens be obtained when endoscopy is performed?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Endoscopy with biopsy for patients with an esophageal GERD syndrome with troublesome dysphagia. Biopsies should target any areas of suspected metaplasia, dysplasia, or in the absence of any visual abnormalities, normal mucosa (at least 5 samples to evaluate for eosinophilic esophagitis).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Routine upper endoscopy in the setting of chronic GERD symptoms to diminish the risk of death from esophageal cancer.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Endoscopic screening for Barrett's esophagus and dysplasia in adults 50 years or older with &gt;5-10 years of heartburn to reduce mortality from esophageal adenocarcinoma.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        What are indications for antireflux surgery, and what is the efficacy of this therapy?",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade A: strongly recommended based on good evidence that it improves important health outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. When antireflux surgery and PPI therapy are judged to offer similar efficacy in a patient with an esophageal GERD syndrome, PPI therapy should be recommended as initial therapy because of superior safety.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. When a patient with an esophageal GERD syndrome is responsive to, but intolerant of, acid suppressive therapy, antireflux surgery should be recommended as an alternative.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade B: recommended with fair evidence that it improves important outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Antireflux surgery for patients with an esophageal GERD syndrome with persistent troublesome symptoms, especially troublesome regurgitation, despite PPI therapy. The potential benefits of antireflux surgery should be weighed against the deleterious effect of new symptoms consequent from surgery, particularly dysphagia, flatulence, an inability to belch, and postsurgery bowel symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade C: balance of benefits and harms is too close to justify a general recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Patients with an extraesophageal GERD syndrome with persistent troublesome symptoms despite PPI therapy should be considered for antireflux surgery. The potential benefits of antireflux surgery should be weighed against the deleterious effect of new symptoms consequent from surgery, particularly dysphagia, flatulence, an inability to belch, and postsurgery bowel symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade D: recommend against, fair evidence that it is ineffective or harms outweigh benefits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. Antireflux surgery for patients with an esophageal syndrome with or without tissue damage who are symptomatically well controlled on medical therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        II. Antireflux surgery as an antineoplastic measure in patients with Barrett's metaplasia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade Insuff: no recommendation, insufficient evidence to recommend for or against",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        I. The use of currently commercially available endoluminal antireflux procedures in the management of patients with an esophageal syndrome.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kahrilas PJ, Shaheen NJ, Vaezi M. American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease. Gastroenterology 2008; 135:1383.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_31_28159=[""].join("\n");
var outline_f27_31_28159=null;
